



Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: A cross-sectional observational study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002235
Article Type:	Research
Date Submitted by the Author:	18-Oct-2012
Complete List of Authors:	Nakajima, Kei; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Oshida, Haruki; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Muneyuki, Toshitaka; Jichi Medical University School of Medicine, First Department of Comprehensive Medicine Saito, Masafumi; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Hori, Yumiko; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Fuchugami, Hiroshi; Social Insurance Omiya General Hospital, Department of Health Care Center Munakata, Hiromi; Social Insurance Omiya General Hospital, Department of Internal Medicine Takei, Masafumi; Jichi Medical University School of Medicine, First Department of Comprehensive Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Nutrition and metabolism, Diabetes and endocrinology
Keywords:	Clinical Epidemiology, Cross sectional studies, Diabetes & endocrinology < INTERNAL MEDICINE, Gastroenterology < INTERNAL MEDICINE, Hepatology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: A cross-sectional observational study

Short title: Low serum amylase and non-alcoholic fatty liver disease

Kei Nakajima^{1,4*}, Haruki Oshida,¹ Toshitaka Muneyuki,² Masafumi Saito,¹

Yumiko Hori,¹ Hiroshi Fuchugami,³ Hiromi Munakata,⁴ Masafumi Kakei²,

*Correspondence to Kei Nakajima, M.D., Ph.D., Division of Clinical Nutrition,
Department of Medical Dietetics, Faculty of Pharmaceutical Sciences, Josai University,
1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan

email: keinaka@josai.ac.jp, Tel +81-49-271-7260, Fax +81-49-271-7260

- 1 Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of
Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama,
350-0295, Japan,
- 2 First Department of Comprehensive Medicine, Saitama Medical Center,
Jichi Medical University School of Medicine, 1-847 Amanuma, Omiya,
Saitama 330-8503, Japan
- 3 Department of Health Care Center, Social Insurance Omiya General Hospital,
453 Bonsai, Kita, Saitama, 331-0805, Japan
- 4 Department of Internal Medicine, Social Insurance Omiya General Hospital,
453 Bonsai, Kita, Saitama, 331-0805, Japan

Key words: serum amylase, NAFLD, metabolic syndrome, diabetes

Word count: 2,779 words

ABSTRACT

Objectives: Low serum amylase (LSA) was reported to be associated with obesity, metabolic syndrome (MetS), and diabetes. However, it is unknown whether LSA is associated with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of MetS and insulin resistance. Therefore, we performed a clinical epidemiological study to investigate this potential association.

Design: A cross-sectional observational study with multivariate analysis.

Setting: Subjects were recruited in a healthcare centre in Saitama, an eastern district of Japan, near Tokyo.

Participants: A total of 1,475 asymptomatic adults aged 30–79 years who underwent detailed medical check-ups and who regularly consumed small amounts of alcohol (< 20 g/day).

Outcome measures: Serum amylase, cardiometabolic risk factors, NAFLD determined by ultrasound, MetS determined by Adult Treatment Panel-III criteria, and diabetes were assessed.

Results: The prevalence of NAFLD increased significantly from 22.5% to 42.4% (all grades) and from 9.2% to 24.0% (moderate or severe grade) from the highest to the lowest quartile of serum amylase. Multiple logistic regression analysis showed that, compared with the highest quartile of serum amylase, the lowest quartile of serum amylase was significantly associated with any-grade NAFLD and with moderate to

1 severe NAFLD, even after adjusting for MetS or diabetes. The association between LSA
2
3
4 and any-grade NAFLD disappeared after further adjustment for body mass index or
5
6
7 waist circumference, whereas the association between LSA and moderate or severe
8
9
10 NAFLD remained statistically significant [odds ratios (95% confidence interval), 2.01
11
12
13 (1.07–3.78) and 2.06 (1.09–3.87), respectively, both $P = 0.01$].
14
15

16 **Conclusions:** Our results suggest that LSA may be a valuable marker for moderate or
17
18
19 severe NAFLD in asymptomatic adults independent of MetS, diabetes, and obesity.
20

21
22 These results warrant confirmation in further studies.
23

24
25 (275/300 words)
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- The clinical relevance of low serum amylase (LSA) is unclear, but it is putatively associated with obesity-related metabolic abnormalities.
- It is unknown whether LSA is associated with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of cardiometabolic disease and insulin resistance.

Key messages

- Our results suggest that LSA is associated with NAFLD independent of metabolic syndrome, diabetes, and obesity.
- LSA may be an independent marker for moderate or severe NAFLD.

Strengths and limitations of this study

- A possible association between LSA and NAFLD was evaluated after fully adjusting for relevant confounding factors.
- NAFLD was diagnosed with ultrasound in this study. Other methods, such as computed tomography and magnetic resonance imaging, may provide more precise assessment of NAFLD.
- This was an observational study and the cause–effect relationship is unknown.

INTRODUCTION

Abnormal serum amylase levels generally reflect overall dysfunction of the pancreas or salivary glands. Although the clinical relevance of elevated serum amylase levels has been extensively studied in relation to various conditions, including acute pancreatitis, pancreatic cancer, ectopic amylase-producing tumours, abdominal trauma, and kidney dysfunction [1-5], the clinical relevance of low serum amylase (LSA) has not been examined. LSA is conventionally considered as a crude marker for diffuse pancreas destruction secondary to pancreatic diseases, such as advanced chronic pancreatitis and cystic fibrosis [6,7]. LSA or low pancreatic amylase is also associated with insulin deficiency in patients with type 1 diabetes and in patients with longstanding type 2 diabetes [8-11]. In our recent community-based study, LSA, defined as a serum amylase concentration of < 60 IU/l, was observed in 25% of asymptomatic individuals [12]. LSA is also associated with metabolic syndrome (MetS), a cluster of cardiovascular risk factors, and diabetes [12,13]. However, obesity is thought to be the strongest predictor of LSA in the asymptomatic general population [12].

In the last two decades, there has been a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide, along with an obesity pandemic [14,15]. NAFLD often progresses to a more severe condition, non-alcoholic steatohepatitis (NASH), and increased hepatic fibrosis is a significant histological feature of advanced NASH. NAFLD is considered to be a hepatic manifestation of

1
2 MetS and insulin resistance [14-18], which suggests that NAFLD consists of a wide
3
4 spectrum of cardiometabolic diseases. It is also possible that NAFLD may reflect more
5
6 pronounced insulin resistance compared with MetS in certain clinical settings, including
7
8 in individuals without diabetes or obesity [17,19,20]. In this context, we hypothesised
9
10 that LSA may be associated with NAFLD independently of MetS and type 2 diabetes.
11
12 The aim of this study was to test this hypothesis and to investigate the clinical relevance
13
14 of LSA, which is often observed in clinical practice. Therefore, we examined the
15
16 associations among serum amylase, cardiometabolic risk factors, NAFLD, hepatic
17
18 fibrosis, MetS, and diabetes in a cross-sectional study of asymptomatic adults.
19
20
21
22
23
24
25
26
27
28
29
30

31 **METHODS**

32 **Protocol and subjects**

33
34 The present report represents a series of observational studies performed in
35
36 collaboration with Josai University, Sakado, Japan, and Social Insurance Omiya
37
38 General Hospital that have been conducted to elucidate the relationships between
39
40 lifestyle-related diseases and cardiometabolic risk factors. We recruited, at random,
41
42 asymptomatic subjects aged 30–79 years who underwent thorough annual medical
43
44 check-ups at the Social Insurance Omiya General Hospital, Saitama, Japan, between
45
46 April 2009 and March 2010. The protocol was approved by The Ethics Committee of
47
48 Josai University and the Council of the Hospital, and informed consent was obtained
49
50
51
52
53
54
55
56
57
58
59
60

1 from all participants.
2
3

4 Subjects with C-reactive protein ≥ 10.0 mg/l, estimated glomerular filtration rate
5
6 (eGFR) ≤ 35 ml/min/1.73 m², serum amylase ≤ 30 IU/l or ≥ 200 IU/l, and those
7
8 suspected of having cancer were excluded from the study. Subjects who habitually
9
10 consumed alcohol ≥ 20 g per day were also excluded from the study. Subjects positive
11
12 for hepatic B virus surface antigen were also excluded. Hepatic C virus infection was
13
14 not measured in this study. We also excluded subjects with other active liver diseases
15
16 not examined, by excluded those with elevated serum liver enzyme levels
17
18 (approximately three times the upper limit of normal): alanine aminotransferase (ALT)
19
20 ≥ 150 IU/ml, aspartate aminotransferase (AST) ≥ 150 IU/ml, or γ -glutamyltransferase
21
22 (GGT) ≥ 150 IU/ml. Consequently, a total of 1,475 individuals were included in this
23
24 study.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Laboratory measurements**

40
41
42 Laboratory and anthropometric tests, and an abdominal ultrasound were performed in
43
44 the early morning after an overnight fast. Serum parameters were measured using an
45
46 AutoAnalyzer (Hitachi, Tokyo, Japan). The serum amylase level was measured using an
47
48 enzymatic method (L-type Amylase; Wako, Tokyo, Japan) with a detection limit of 1.7
49
50 IU/l, and a run-to-run coefficient of variation of $< 5.0\%$.
51
52
53
54

55
56
57 Abdominal ultrasound for the detection of fatty liver was carried out by
58
59
60

1 echography specialists at the Social Insurance Omiya General Hospital. Fatty liver in
2
3
4 the eligible subjects was defined as NAFLD because they consumed < 20 g of alcohol
5
6
7 per day [14]. The severity of NAFLD was graded into three categories: mild NAFLD, a
8
9
10 slight increase in liver echogenicity with normal visualisation of the diaphragm and the
11
12
13 portal veins; moderate NAFLD, a moderate increase in liver echogenicity with slightly
14
15
16 impaired visualisation of the diaphragm and the portal veins; and severe NAFLD, a
17
18
19 substantial increase in liver echogenicity with poor or no visualisation of the diaphragm
20
21
22 and the portal veins. Since it is possible that mild NAFLD could include a normal liver,
23
24
25 we defined overt NAFLD as moderate or severe NAFLD. The following liver fibrosis
26
27
28 scores, the AST/ALT ratio [21], FIB-4, and AST to platelet ratio index (APRI), were
29
30
31 calculated in all patients, using previously published formulae:

32
33
34
$$\text{FIB-4} = \text{age (years)} \times \text{AST/platelet count (10}^9\text{/l)} \times \text{ALT}^{1/2}$$
 [22];

35
36
37
$$\text{APRI} = [(\text{AST/the upper limit of normal of AST} = 35) \times 100] / \text{platelet count (10}^9\text{/l)}$$
 [23].

38
39 The diagnosis of MetS was based on the Adult Treatment Panel-III criteria [24] with
40
41
42 the following cut-off limits: 1) systolic blood pressure \geq 130 mmHg or diastolic blood
43
44
45 pressure \geq 85 mmHg; 2) triglyceride \geq 150 mg/dl; 3) high-density
46
47
48 lipoprotein-cholesterol < 40 mg/dl for men and < 50 mg/dl for women; 4) fasting
49
50
51 plasma glucose \geq 100 mg/dl; and 5) waist circumference \geq 90 cm for men and \geq 80 cm
52
53
54 for women. Subjects meeting three or more of these criteria, including treatment for any
55
56
57 of these disorders, were defined as having MetS. Diabetes was defined as fasting plasma
58
59
60

1
2 glucose \geq 126 mg/dl or glycosylated haemoglobin (HbA1c) \geq 6.5% (by the National
3
4 Glycoprotein Standardization Program (NGSP)) according to the American Diabetes
5
6 Association criteria [25], or treatment with oral hypoglycaemic drugs or insulin. HbA1c
7
8 (Japan Diabetes Society [JDS]) was converted to HbA1c (NGSP) units using the
9
10 officially certified formula: HbA1c (NGSP) (%) = $1.02 \times \text{JDS} (\%) + 0.25\%$ [26].
11
12
13
14
15

16 Since serum amylase can be affected by kidney function because of its excretion
17
18 by the kidney [4,5], eGFR was considered as a confounding factor and was calculated
19
20 using the following equation for Japanese subjects [27]: $\text{eGFR} (\text{ml}/\text{min}/1.73 \text{ m}^2) = 194$
21
22 $\times \text{serum Cr}^{-1.094} \times \text{age}^{-0.287}$ (if female) $\times 0.739$. Here, Cr = serum creatinine
23
24
25
26
27
28 concentration (mg/dl).
29
30
31
32

33 **Statistical analysis**

34
35
36 Data are expressed as the mean \pm standard deviation (SD) or median (interquartile
37
38 range). Subjects were divided into quartiles according to serum amylase levels, where
39
40 Q1 is the highest quartile and Q4 is the lowest quartile. *P*-values for continuous
41
42 variables were determined using analysis of variance (ANOVA) or the Mann-Whitney
43
44 *U* test, and for categorical variables using the χ^2 test. Highly skewed values (ALT, AST,
45
46 GGT, APRI, and triglyceride) were log-transformed before analysis. Subjects were also
47
48 stratified into four groups according to the grade of NAFLD (i.e., normal, mild,
49
50 moderate, and severe NAFLD). Multivariate logistic regression models were used to
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

examine the associations of quartiles (Q2–4) of serum amylase with any-grade NAFLD (NAFLD-AG), and with overt NAFLD relative to Q1, controlling for relevant confounding factors, including MetS, diabetes, and body mass index (BMI) or waist circumference (WC). To elucidate any association between LSA and NAFLD, we examined the associations between LSA and NAFLD-AG, and between LSA and overt NAFLD. This analysis yielded odds ratios (OR) and 95% confidential intervals (95% CI). Tests for linear trends (*P* for trend) were calculated by treating the quartiles as a continuous variable (i.e., 1–4), and the same model analysis was conducted. Statistical analyses were performed using SPSS software version 18.0 (SPSS-IBM, Chicago, IL, USA) and Statview version 5.0 (SAS Institute, Cary, NC, USA). Values of *P* < 0.05 were considered to be statistically significant.

RESULTS

The clinical characteristics of the subjects according to the quartile of serum amylase are shown in Table 1. The mean and median values of most clinical parameters, including platelet count and eGFR, increased significantly with as serum amylase decreased, although there was a significant trend for subjects with lower amylase levels to be younger. No significant trend in HbA1c was observed against quartiles of serum amylase. The prevalence of NAFLD-AG and overt NAFLD increased significantly, from 22.5% to 42.4% and from 9.2% to 24%, respectively, from the highest (Q1) to the

1 lowest serum amylase quartile (Q4). Log-transformed serum ALT and GGT increased
2
3
4 significantly, whereas the AST/ALT ratio, APRI, and FIB-4 decreased significantly with
5
6
7 decreasing serum amylase quartile.
8
9

10 When subjects were stratified according to NAFLD grade, serum amylase decreased
11
12 significantly with advancing grade of NAFLD (Figure 1). When subjects were further
13
14 stratified according to sex, there was no significant difference between men and women.
15
16 However, when the subjects were stratified according to high or low BMI (Figure 2),
17
18 serum amylase levels were significantly lower in overweight/obese subjects (BMI \geq
19
20 25.0 kg/m², mean \pm SD BMI, 27.3 \pm 2.3 kg/m², n = 1,121) than in lean subjects (BMI <
21
22 25.0 kg/m², mean \pm SD BMI, 21.6 \pm 2.0 kg/m², n = 354). Serum amylase levels in lean
23
24
25 subjects decreased significantly with advancing grade of NAFLD, whereas those in
26
27
28 obese subjects did not. Significant differences between lean and obese subjects were
29
30
31 only observed only in subjects with a normal liver or mild NAFLD. We did not conduct
32
33
34 an analysis by further stratification according to MetS or diabetes because of the small
35
36
37 proportion of subjects (both, < 10%).
38
39
40
41
42
43
44

45 Multiple logistic regression analysis showed that, compared with the highest
46
47 quartile of serum amylase (\geq 90 IU/l, Q1), the lowest quartile (< 60 IU/l, Q4) was
48
49 significantly associated with NAFLD-AG even after adjusting for confounders plus
50
51
52 MetS or diabetes (Table 2, Models 4 and 5). In these conditions, MetS (OR: 3.66, 95%
53
54
55 CI: 2.37–5.65) and diabetes (OR: 1.96, 95% CI: 1.25–3.05) were significantly
56
57
58
59
60

1 associated with Q4 of serum amylase (data not shown). However, these associations
2
3 were markedly attenuated and were no longer statistically significant after adjusting for
4
5 clinical confounders plus BMI or WC (Models 6 and 7), although there was a trend
6
7 towards an association among the quartiles of serum amylase.
8
9

10
11
12
13 When we excluded subjects with mild grade NAFLD (n = 242) and repeated the
14
15 analysis (Table 3), we detected stronger significant associations between Q4 and overt
16
17 NAFLD. These associations were also moderately attenuated after additional adjustment
18
19 for BMI or WC, but they remained statistically significant (Models 6 and 7). In this
20
21 condition, BMI (OR: 1.65, 95% CI: 1.51–1.80) and WC (OR: 1.21, 95% CI: 1.17–1.25)
22
23 were significantly associated with overt NAFLD (data not shown).
24
25
26
27
28
29
30
31
32

33 **DISCUSSION**

34
35
36 For the last few decades, NAFLD has been considered as a manifestation of MetS and
37
38 insulin resistance [14-18]. In this context, the present study showed that LSA was
39
40 significantly associated with NAFLD-AG in asymptomatic adults, independent of MetS,
41
42 diabetes, and sex. Furthermore, LSA may be indicative of overt NAFLD, i.e., moderate
43
44 or severe NAFLD, independent of obesity. These findings are not inconsistent because
45
46 NAFLD may reflect insulin resistance, more so than MetS, in individuals without
47
48 diabetes or obesity [17,19,20].
49
50
51
52
53
54
55

56
57 This study provided evidence that NAFLD can occur in lean individuals, who
58
59
60

1 accounted for 37.8% (62/104) of subjects with moderate NAFLD and 19.3% (11/57) of
2
3
4 subjects with severe NAFLD (Figure 2). This is consistent with the results of
5
6
7 multivariate logistic analysis, where there was a significant trend for NAFLD against
8
9
10 quartiles of serum amylase, and the significant association between the lowest quartile
11
12
13 of serum amylase and NAFLD remained after adjusting for BMI and WC (Tables 2 and
14
15
16 3). Notably, we found no significant difference in serum amylase between lean and
17
18
19 obese subjects with overt NAFLD, suggesting that the effects of obesity on serum
20
21
22 amylase are apparent in subjects with a normal liver or with mild NAFLD, but not in
23
24
25 subjects with overt NAFLD. Several studies have shown that NAFLD occurs in
26
27
28 non-obese people, although the prevalence of NAFLD in non-obese subjects is lower
29
30
31 than that in obese subjects [19,20,28]. Therefore, other than obesity, factors not
32
33
34 examined in this study might also explain the association between LSA and NAFLD.
35
36
37 Insulin resistance and obesity-related hormones, such as leptin, may be potential factors,
38
39
40 because insulin resistance and energy imbalance are common pathophysiological
41
42
43 findings in obese individuals [17,29]. Indeed, obesity plus insulin resistance is more
44
45
46 closely associated with metabolic abnormalities and NAFLD than is obesity without
47
48
49 insulin resistance [17]. Hyperinsulinaemia caused by insulin resistance stimulates *de*
50
51
52 *novo* lipogenesis in the liver through sterol regulatory element binding protein-1c
53
54
55 (SREBP-1c) [30], irrespective of the influx of fatty acid from a meal and lipolysis in
56
57
58 adipose tissues. Additionally, we recently reported a latent association between LSA and
59
60

1
2 insulin resistance in a small study of asymptomatic middle-aged adults [31], supporting
3
4 the hypothesis that LSA may be associated with NAFLD, at least in part through insulin
5
6 resistance. However, further large epidemiological studies evaluating insulin resistance
7
8
9
10 are needed to confirm our hypothesis.
11

12
13 As another explanation, systemic ectopic fat deposition in organs including the
14
15 pancreas (i.e., fatty pancreas) might contribute to the observed associations because
16
17 intrapancreatic fat, particularly intralobular pancreatic fat, was reported to be associated
18
19 with NAFLD and MetS [32,33]. An animal study showed that obese mice had a heavier
20
21 pancreas and more intrapancreatic fat [34]. Therefore, systemic fat deposits in multiple
22
23 organs may be a common cause underlying the association between NAFLD and overall
24
25 pancreatic dysfunction, which may result in impaired exocrine function, characterised as
26
27 LSA. Gene polymorphisms of patatin-like phospholipase domain containing 3
28
29 (PNPLA3) may also contribute to the strength of these associations. For example, a
30
31 common variant of the PNPLA3 gene (rs738409) was reported to be associated with
32
33 increased hepatic fat content (i.e., NAFLD) [35]. In the mouse liver,
34
35 adiponutrin/PNPLA3 gene expression is under the direct transcriptional control of
36
37 SREBP-1c, in response to insulin [36]
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Similar to an earlier study [12], HbA1c was not associated with LSA, probably
52
53 because most subjects in the lowest quartile of serum amylase in this study had no or
54
55 only mild insulin resistance or mild hyperinsulinaemia, which is likely compensated for
56
57
58
59
60

1 and results in euglycaemia. In such conditions, fasting plasma glucose would increase
2
3
4 linearly, as observed in Table 1, in response to insulin resistance, particularly in the
5
6
7 early stage of diabetes [37,38].
8
9

10 To date, some markers have been considered for screening for NAFLD and mild
11
12 hepatic fibrosis [39-41]. In this study, the AST/ALT ratio decreased significantly with
13
14 the decreasing quartile of serum amylase. However, while the platelet count increased
15
16 significantly, both APRI and Fib-4 decreased (Table 1). Consequently, hepatic fibrosis is
17
18 unlikely to be associated with NAFLD in this study. A plausible explanation is that this
19
20 study mostly consisted of non-obese individuals, with a small proportion having MetS
21
22 and diabetes, resulting in a lower likelihood of advanced hepatic fibrosis and NASH. In
23
24 addition, more than half of the subjects in this study had repeatedly undergone medical
25
26 check-ups, which may promote consciousness of healthcare and favourable lifestyles.
27
28
29
30
31
32
33
34
35
36
37
38

39 **Limitations**

40
41 Several limitations should be mentioned. First, NAFLD was diagnosed by ultrasound
42
43 rather than by histological examination, the gold standard technique for the diagnosis of
44
45 NAFLD. Thus, NAFLD and the degree of hepatic fibrosis could be inaccurately
46
47 evaluated, particularly in the early stages. Nevertheless, the ultrasound method is
48
49 effective for screening NAFLD, with an overall sensitivity of 89% and specificity of
50
51 93% [42]. Despite this, in cases of mild NAFLD with a small amount of fat (< 30%),
52
53
54
55
56
57
58
59
60

1 the sensitivity is reduced. For this reason, we examined the association of LSA with
2
3
4 NAFLD-AG and with overt NAFLD. Second, hepatitis C virus infection was not
5
6
7 measured in this study. However, the prevalence of hepatitis C infection was reported to
8
9
10 be 0.49–0.98% in Japanese blood donors [43,44]. Therefore, hepatitis C infection is
11
12
13 unlikely to profoundly modify the association between LSA and NAFLD, although
14
15
16 hepatitis C infection can contribute to the development of NAFLD [45]. Third, because
17
18
19 of the cross-sectional nature of the study, we could not determine the cause–effect
20
21
22 relationship between LSA and NAFLD. However, in a previous retrospective study [12],
23
24
25 subjects with LSA at baseline were more likely to develop MetS-related metabolic
26
27
28 abnormalities 5 years later. A longitudinal prospective study or a clinical intervention
29
30
31 trial will be needed to elucidate the causality of the associations reported here.
32
33
34
35

36 **Conclusion**

37
38
39 Our results suggest that LSA may be associated with NAFLD, particularly moderate or
40
41
42 severe NAFLD, in asymptomatic adults. This association was independent of MetS,
43
44
45 diabetes, and obesity. Further studies are needed to confirm the observed associations,
46
47
48 and to explore the clinical relevance of LSA.
49
50
51
52
53

54 **Acknowledgments** None
55
56
57
58
59
60

1 **Competing interests** The authors declare that they have no competing interests.
2
3

4 **Funding**
5

6
7 This research received no specific grant from any funding agency in the public,
8
9
10 commercial, or not-for-profit sectors.
11
12

13
14
15 **Contributors**
16

17
18 KN, HM, and MK designed the collaborative project; KN, HO, TM, and HF collected
19
20 and analysed the data; KN, HO, MS, and YH researched and evaluated the literature;
21
22 and KN wrote the first draft of the manuscript. All authors reviewed and edited the
23
24
25 manuscript, and approved the final version of the manuscript.
26
27
28
29

30
31
32 **Data sharing statement** There are no additional data available.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Yegneswaran B, Pitchumoni CS. Yegneswaran B, et al. When should serum amylase and lipase levels be repeated in a patient with acute pancreatitis? *Cleve Clin J Med* 2010;77:230-231.
2. Skrha J, Stěpán J. Clinical significance of amylase isoenzyme determination. *Acta Univ Carol Med Monogr* 1987;120:1-81.
3. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? *Gastroenterol Clin North Am* 1990;19:793-810.
4. Junge W, Mályusz M, Ehrens HJ. The role of the kidney in the elimination of pancreatic lipase and amylase from blood. *J Clin Chem Clin Biochem* 1985;23:387-392.
5. Collen MJ, Ansher AF, Chapman AB, et al. Serum amylase in patients with renal insufficiency and renal failure. *Am J Gastroenterol* 1990;85:1377-1380.
6. Domínguez-Muñoz JE, Pieramico O, Büchler M, et al. Ratios of different serum pancreatic enzymes in the diagnosis and staging of chronic pancreatitis. *Digestion* 1993;54:231-236.
7. Wolf RO, Hubbard VS, Gillard BK, et al. Three methods compared for determination of pancreatic and salivary amylase activity in serum of cystic fibrosis patients. *Clin Chem*. 1986;32:296-300.
8. Frier BM, Faber OK, Binder C, et al. The effect of residual insulin secretion on

- 1
2 exocrine pancreatic function in juvenile-onset diabetes mellitus. *Diabetologia*
3
4
5 1978;14:301-304.
6
7
8 9. Dandona P, Freedman DB, Foo Y, et al. Exocrine pancreatic function in diabetes
9
10 mellitus. *J Clin Pathol* 1984;37:302-306
11
12
13 10. Swislocki A, Noth R, Hallstone A, et al. Secretin-stimulated amylase release into
14
15 blood is impaired in type 1 diabetes mellitus. *Horm Metab Res* 2005;37:326-330.
16
17
18 11. Aughsteen AA, Abu-Umair MS, Mahmoud SA. Biochemical analysis of serum
19
20 pancreatic amylase and lipase enzymes in patients with type 1 and type 2 diabetes
21
22 mellitus. *Saudi Med J* 2005;26:73-77.
23
24
25
26
27 12. Nakajima K, Nemoto T, Muneyuki T, et al. Low serum amylase in association with
28
29 metabolic syndrome and diabetes: A community-based study. *Cardiovasc Diabetol.*
30
31
32 2011;10:34.
33
34
35
36 13. Lee JG, Park SW, Cho BM, et al. Serum amylase and risk of the metabolic
37
38 syndrome in Korean adults. *Clin Chim Acta.* 2011; 412:1848-53
39
40
41
42 14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of
43
44 an AASLD Single Topic Conference. *Hepatology.* 2003;37:1202-1219.
45
46
47
48 15. Smith BW, Adams LA. Non-alcoholic fatty liver disease. *Crit Rev Clin Lab Sci.*
49
50 2011;48:97-113.
51
52
53
54 16. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. *Diabetes.*
55
56 2011;60:2011-2017.
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med.* 2008;168:1609-1616.
 18. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. *J Clin Endocrinol Metab.* 2005; 90:1578-1582.
 19. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. *Arch Intern Med.* 2004;164:2169-7215.
 20. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. *Diabetes Care.* 2008;31:562-568
 21. Iacobellis A, Marcellini M, Andriulli A, et al. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. *World J Gastroenterol.* 2006;12:7821-7825.
 22. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. *Hepatology.* 2007;46:32-36.
 23. Fibrosis score Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38:518–526.
 24. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and

- 1 Blood Institute Scientific Statement. *Circulation*. 2005;112:2735-2752.
- 2
- 3
- 4 25. American Diabetes Association. Diagnosis and classification of diabetes mellitus.
- 5
- 6
- 7 Diabetes Care. 2010; 33 Suppl 1:S62-69.
- 8
- 9
- 10 26. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of
- 11
- 12 glycated hemoglobin in Japan: From Japan Diabetes Society to National
- 13
- 14 Glycohemoglobin Standardization Program values. *Journal of Diabetes*
- 15
- 16 Investigation 2012;3:39-40
- 17
- 18
- 19
- 20
- 21
- 22 27. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum
- 23
- 24 creatinine in Japan. *Am J Kidney Dis*. 2009;53:982–992.
- 25
- 26
- 27
- 28 28. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country
- 29
- 30 has a high prevalence of nonalcoholic fatty liver and significant liver disease.
- 31
- 32
- 33 Hepatology. 2010;51:1593-1602.
- 34
- 35
- 36
- 37 29. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy
- 38
- 39 balance. *J Clin Invest*. 2011;121:2087-2093.
- 40
- 41
- 42 30. Dentin R, Pégrier JP, Benhamed F, et al. Hepatic glucokinase is required for the
- 43
- 44 synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene
- 45
- 46 expression. *J Biol Chem*. 2004;279:20314-20326.
- 47
- 48
- 49
- 50
- 51 31. Muneyuki T, Nakajima K, Aoki A, et al. Latent associations of low serum amylase
- 52
- 53
- 54 with decreased plasma insulin levels and insulin resistance in asymptomatic
- 55
- 56 middle-aged adults. *Cardiovasc Diabetol*. 2012; 11:80.
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
32. van Geenen EJ, Smits MM, Schreuder TC, et al. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. *Pancreas*. 2010;39:1185-1190.
 33. Sepe PS, Ohri A, Sanaka S, et al. A prospective evaluation of fatty pancreas by using EUS. *Gastrointest Endosc*. 201; 73:987-993.
 34. Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. *HPB (Oxford)*. 2007;9:312-318.
 35. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology*. 2011;53:1883-1894.
 36. Dubuquoy C, Robichon C, Lasnier F, et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. *J Hepatol*. 2011;55:145-153.
 37. Reaven G. Wanted!: a standardized measurement of plasma insulin concentration. *Arterioscler Thromb Vasc Biol*. 2011; 31:954-955.
 38. Robins SJ, Lyass A, Zachariah JP, et al. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol*. 2011;31:1208-1214.
 39. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. *Gastroenterology*. 1988; 95(3):734-9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
40. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45:846-854.
41. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut*. 2010;59:1265-1269.
42. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol*. 1991;43:26-31.
43. Yamaguchi K, Kiyokawa H, Machida J, Obayashi A, Nojiri N, Ueda S, Takatsuki K. Seroepidemiology of hepatitis C virus infection in Japan and HCV infection in haemodialysis patients. *FEMS Microbiol Rev*. 1994 Jul;14(3):253-8.
44. Tanaka J, Kumagai J, Katayama K, Komiya Y, Mizui M, Yamanaka R, Suzuki K, Miyakawa Y, Yoshizawa H. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. *Intervirology*. 2004;47(1):32-40.
45. Pattullo V, Douglas MW, George J. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? *Expert Rev Gastroenterol Hepatol*. 2011 Apr;5(2):265-77.

Figure Legends

Figure 1 Serum amylase levels according to the grade of NAFLD and sex. Serum amylase levels decreased significantly with advancing grade of NAFLD in both sexes (ANOVA, both $P = 0.0001$). There was no significant difference between men and women (two-way ANOVA, $P = 0.45$). *Number of subjects in each group. Bars represent standard errors.

Figure 2 Serum amylase levels according to the grade of NAFLD and obesity. Obesity was defined as $BMI \geq 25.0 \text{ kg/m}^2$. Serum amylase levels decreased significantly with advancing grade of NAFLD in lean subjects (ANOVA, $P = 0.01$), but not in obese subjects ($P = 0.33$). An overall significant difference was observed between lean and obese subjects (two-way ANOVA, $P = 0.03$). *Number of subjects in each group; † $P = 0.0001$ and ‡ $P = 0.02$ for lean versus obese subjects (Mann–Whitney U test). Bars represent standard errors.

Table 1. Characteristics of subjects stratified according to quartiles of serum amylase

	Total	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> value
n	1,475	369	371	381	354	
Age, y	55.1 ± 12.2	58.4 ± 11.8	56.4 ± 12.2	52.9 ± 11.7	52.7 ± 12.0	< 0.0001
Men, n (%)	747 (50.6)	178 (48.2)	176 (47.4)	205 (53.8)	188 (53.1)	0.19
BMI, kg/m ²	23.0 ± 3.2	21.9 ± 2.7	22.6 ± 3.2	23.3 ± 3.1	24.1 ± 3.4	< 0.0001
WC, cm	80.8 ± 8.9	78.2 ± 8.3	79.9 ± 8.8	81.8 ± 8.8	83.2 ± 9.1	< 0.0001
Systolic blood pressure, mmHg	120 ± 18.9	119 ± 18.5	119 ± 18.7	120 ± 18.9	123 ± 19.1	0.007
Diastolic blood pressure, mmHg	74.1 ± 12.6	72.6 ± 12.2	73.1 ± 11.9	74.5 ± 13.4	76.1 ± 12.4	0.0009
Platelet count, 10 ⁹ /L	235 ± 53.4	228 ± 53.8	235 ± 53.1	237 ± 51.1	241 ± 55.2	0.01
ALT, IU/l	18 (14–25)	18 (14–23)	17 (14–23)	18 (14–25)	19 (14–29)	< 0.0001
AST, IU/l	20 (17–24)	21 (19–25)	20 (17–24)	19 (17–23)	20 (17–24)	0.04
AST/ALT	1.15 ± 0.36	1.24 ± 0.35	1.20 ± 0.37	1.12 ± 0.33	1.04 ± 0.35	< 0.0001
APRI	0.25 (0.20–0.33)	0.28 (0.22–0.34)	0.25 (0.21–0.33)	0.24 (0.20–0.30)	0.24 (0.19–0.32)	0.0006
FIB-4	1.13 (0.82–1.52)	1.33 (0.98–1.76)	1.20 (0.89–1.59)	1.05 (0.76–1.38)	0.98 (0.70–1.36)	< 0.0001
GGT, IU/l	22 (16–33)	20 (15–31)	20 (16–30)	23 (16–34)	24 (17–38)	0.0009
C-reactive protein	0.4 (0.3–0.8)	0.3 (0.3–0.63)	0.4 (0.3–0.8)	0.4 (0.3–0.8)	0.5 (0.3–1.1)	< 0.0001
Amylase, IU/l	77.3 ± 24.9	110 ± 22.0	81.3 ± 4.7	66.6 ± 4.1	50.3 ± 7.0	—
(range)	(30–200)	(90–200)	(74–89)	(60–73)	(30–59)	
Triglyceride, mg/dl	88 (64–128)	83 (63–121)	84 (62–123)	88 (65–128)	100 (65–143)	0.001
HDL-cholesterol, mg/dl	61.2 ± 15.0	64.2 ± 15.4	62.6 ± 14.8	59.8 ± 14.6	58.3 ± 14.5	< 0.0001
Fasting plasma glucose, mg/dl	99.6 ± 16.7	97.5 ± 13.4	97.4 ± 11.4	101 ± 19.4	103 ± 20.4	< 0.0001
HbA1c (NGSP), %	5.7 ± 0.6	5.7 ± 0.5	5.7 ± 0.4	5.7 ± 0.6	5.8 ± 0.7	0.14
eGFR, ml/min/1.73m ²	75.0 ± 13.9	71.0 ± 14.3	74.3 ± 12.9	76.0 ± 14.2	78.7 ± 13.1	< 0.0001
ATP-III-Metabolic syndrome, n (%)	139 (9.4)	16 (4.3)	23 (6.2)	47 (12.3)	53 (15.0)	< 0.0001
Diabetes, n (%)	114 (7.7)	19 (5.1)	17 (4.6)	34 (8.9)	44 (12.4)	0.0002

NAFLD of all grades, n (%)	463 (31.4)	83 (22.5)	97 (26.1)	133 (34.9)	150 (42.4)	< 0.0001
Moderate to severe NAFLD, n (%)	221 (15.0)	34 (9.2)	42 (11.3)	60 (15.7)	85 (24.0)	< 0.0001
Medical history of						
Cardiovascular diseases, n (%)	55 (3.7)	11 (3.0)	20 (5.4)	11 (2.9)	13 (3.7)	0.24
Stroke, n (%)	26 (1.8)	12 (3.3)	6 (1.6)	4 (1.1)	4 (1.1)	0.08
Medications for						
Hypertension, n (%)	237 (16.1)	64 (17.3)	47 (12.7)	67 (17.6)	59 (16.7)	0.22
Hypercholesterolemia, n (%)	177 (12.0)	56 (15.2)	43 (11.6)	34 (8.9)	44 (12.4)	0.07
Diabetes, n (%)	56 (3.8)	12 (3.3)	12 (3.2)	15 (3.9)	17 (4.8)	0.65
Current smoker, n (%)	273 (18.5)	40 (10.8)	50 (13.5)	86 (22.6)	97 (27.4)	< 0.0001
Everyday alcohol consumers, n (%)	229 (15.5)	51 (13.8)	59 (15.9)	66 (17.3)	53 (15.0)	0.61
Regular exercise, n (%)	507 (34.4)	144 (39.0)	135 (36.4)	125 (32.9)	103 (29.1)	0.03

Data are means \pm SD and medians (interquartile range). *P*-values for continuous variables and categorical variables were determined by analysis of variance and the χ^2 test, respectively. Regular exercise: \geq 30 min exercise per session at least twice a week.

Table 2. Odds ratios for NAFLD-AG according to serum amylase quartiles

Serum amylase quartiles	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> for trend
n	369	371	381	354	
Model 1	1	1.22 (0.87–1.71)	1.85 (1.34–2.55)	2.53 (1.84–3.50)	< 0.0001
Model 2	1	1.28 (0.91–1.81)	1.96 (1.39–2.74)	2.74 (1.95–3.85)	< 0.0001
Model 3	1	1.35 (0.93–1.97)	2.03 (1.41–2.94)	2.41 (1.66–3.51)	< 0.0001
Model 4	1	1.25 (0.86–1.82)	1.83 (1.26–2.65)	2.18 (1.49–3.18)	< 0.0001
Model 5	1	1.31 (0.90–1.90)	2.00 (1.39–2.89)	2.36 (1.62–3.44)	< 0.0001
Model 6	1	0.99 (0.66–1.49)	1.34 (0.89–2.01)	1.42 (0.94–2.15)	0.04
Model 7	1	1.02 (0.68–1.53)	1.30 (0.87–1.94)	1.49 (0.99–2.24)	0.03

Model 1: unadjusted

Model 2: adjusted for age, sex, and current smoking (*versus* non-smokers)

Model 3: Model 2 plus adjustment for log-transformed ALT, regular exercise (*versus* infrequent exercise), daily alcohol consumption (*versus* infrequent/no alcohol consumption), eGFR, past history of heart diseases and stroke, and medications for hypertension, diabetes, and dyslipidemia.

Model 4: Model 3 plus adjustment for diabetes, but excluding medications for hypertension, diabetes, and dyslipidemia.

Model 5: Model 3 plus adjustment for metabolic syndrome, but excluding medications for hypertension, diabetes, and dyslipidemia.

Model 6: Model 3 plus adjustment for BMI


Model 7: Model 3 plus adjustment for WC

Table 3. Odds ratios of each serum amylase for NAFLD of moderate or severe grade


Serum amylase quartiles	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> for trend
N*	320	316	308	289	
Model 1	1	1.29 (0.80–2.09)	2.04 (1.29–3.20)	3.51 (2.27–5.42)	< 0.0001
Model 2	1	1.36 (0.83–2.22)	2.14 (1.33–3.44)	3.81 (2.40–6.05)	< 0.0001
Model 3	1	1.61 (0.91–2.86)	2.32 (1.32–4.07)	3.45 (1.99–6.00)	< 0.0001
Model 4	1	1.48 (0.84–2.64)	2.11 (1.19–3.73)	2.97 (1.70–5.20)	< 0.0001
Model 5	1	1.56 (0.89–2.75)	2.32 (1.33–4.04)	3.26 (1.88–5.66)	< 0.0001
Model 6	1	1.05 (0.54–2.03)	1.44 (0.76–2.72)	2.01 (1.07–3.78)	0.01
Model 7	1	1.06 (0.55–2.05)	1.37 (0.73–2.59)	2.06 (1.09–3.87)	0.01

*Subjects with mild NAFLD (n = 242) were excluded from this analysis. Model 1 to Model 7 are the same as in **Table 2**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: A cross-sectional observational study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002235.R1
Article Type:	Research
Date Submitted by the Author:	11-Dec-2012
Complete List of Authors:	Nakajima, Kei; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Oshida, Haruki; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Muneyuki, Toshitaka; Jichi Medical University School of Medicine, First Department of Comprehensive Medicine Saito, Masafumi; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Hori, Yumiko; Josai University, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences Fuchugami, Hiroshi; Social Insurance Omiya General Hospital, Department of Health Care Center Takei, Masafumi; Jichi Medical University School of Medicine, First Department of Comprehensive Medicine Munakata, Hiromi; Social Insurance Omiya General Hospital, Department of Internal Medicine
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Nutrition and metabolism, Diabetes and endocrinology
Keywords:	Clinical Epidemiology, Cross sectional studies, Diabetes & endocrinology < INTERNAL MEDICINE, Gastroenterology < INTERNAL MEDICINE, Hepatology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts

1
2 **Independent association between low serum amylase and non-alcoholic fatty liver**
3
4 **disease in asymptomatic adults: A cross-sectional observational study**
5
6
7
8
9

10 Short title: Low serum amylase and non-alcoholic fatty liver disease
11
12
13

14
15
16 Kei Nakajima^{1,4*}, Haruki Oshida¹ Toshitaka Muneyuki,² Masafumi Saito,¹ Yumiko
17
18 Hori,¹ Hiroshi Fuchugami,³ Masafumi Kakei², Hiromi Munakata⁴
19
20
21
22
23

24
25 *Correspondence to Kei Nakajima, M.D., Ph.D., Division of Clinical Nutrition,
26

27 Department of Medical Dietetics, Faculty of Pharmaceutical Sciences, Josai University,
28

29
30 1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
31

32
33 email: keinaka@josai.ac.jp; Tel: +81-49-271-7260; Fax: +81-49-271-7260
34
35
36
37
38

39 1 Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of
40
41 Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295,
42
43
44
45 Japan
46

47
48 2 First Department of Comprehensive Medicine, Saitama Medical Center, Jichi Medical
49
50
51 University School of Medicine, 1-847 Amanuma, Omiya, Saitama 330-8503, Japan
52

53
54 3 Department of Health Care Center, Social Insurance Omiya General Hospital, 453
55
56
57 Bonsai, Kita, Saitama 331-0805, Japan
58
59
60

1
2 4 Department of Internal Medicine, Social Insurance Omiya General Hospital, 453
3

4
5 Bonsai, Kita, Saitama 331-0805, Japan
6
7
8
9

10 **Key words:** serum amylase, NAFLD, metabolic syndrome, diabetes
11

12
13 **Word count:** 3334 words
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objectives: Low serum amylase (LSA) was reported to be associated with obesity, metabolic syndrome (MetS), and diabetes. However, it is unknown whether LSA is associated with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of MetS and insulin resistance. Therefore, we performed a clinical epidemiological study to investigate this potential association.

Design: A cross-sectional observational study with multivariate analysis.

Setting: Subjects were recruited in a healthcare centre in Saitama, an eastern district of Japan, near Tokyo.

Participants: A total of 1,475 asymptomatic adults aged 30–79 years who underwent detailed medical check-ups and who regularly consumed small amounts of alcohol (< 20 g/day).

Outcome measures: Serum amylase, cardiometabolic risk factors, NAFLD determined by ultrasound, MetS determined by Adult Treatment Panel-III criteria, and diabetes were assessed.

Results: The prevalence of NAFLD increased significantly from 22.5% to 42.4% (all grades) and from 9.2% to 24.0% (moderate or severe grade) from the highest to the lowest quartile of serum amylase. Multiple logistic regression analysis showed that, compared with the highest quartile of serum amylase, the lowest quartile of serum amylase was significantly associated with any-grade NAFLD and with moderate to

1
2 severe NAFLD, even after adjusting for MetS or diabetes. The association between LSA
3
4 and any-grade NAFLD disappeared after further adjustment for body mass index or
5
6 waist circumference, whereas the association between LSA and moderate or severe
7
8 NAFLD remained statistically significant [odds ratios (95% confidence interval), 2.01
9
10 (1.07–3.78) and 2.06 (1.09–3.87), respectively, both $P = 0.01$].
11
12
13
14
15

16 **Conclusions:** Our results suggest that LSA may be associated with moderate or severe
17
18 NAFLD in asymptomatic adults independent of MetS, diabetes, and obesity. These
19
20 results warrant confirmation in further studies.
21
22
23

24 (274/300 words)
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- The clinical relevance of low serum amylase (LSA) is unclear, but it is putatively associated with obesity-related metabolic abnormalities.
- It is unknown whether LSA is associated with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of cardiometabolic disease and insulin resistance.

Key messages

- Our results suggest that LSA is associated with NAFLD independent of metabolic syndrome, diabetes, and obesity.
- LSA may be an independent marker for moderate or severe NAFLD.

Strengths and limitations of this study

- A possible association between LSA and NAFLD was evaluated after fully adjusting for relevant confounding factors.
- NAFLD was diagnosed with ultrasound in this study. Other methods, such as computed tomography, magnetic resonance imaging, and fibroscan, may provide more precise assessment of NAFLD.
- This was an observational study and the cause–effect relationship is unknown.

INTRODUCTION

Abnormal serum amylase levels generally reflect overall dysfunction of the pancreas or salivary glands. Although the clinical relevance of elevated serum amylase levels has been extensively studied in relation to various conditions, including acute pancreatitis, pancreatic cancer, ectopic amylase-producing tumours, abdominal trauma, and kidney dysfunction [1-5], the clinical relevance of low serum amylase (LSA) has not been examined. LSA is conventionally considered as a crude marker for diffuse pancreas destruction secondary to pancreatic diseases, such as advanced chronic pancreatitis and cystic fibrosis [6,7]. LSA or low pancreatic amylase is also associated with insulin deficiency in patients with type 1 diabetes and in patients with longstanding type 2 diabetes [8-11]. In our recent community-based study, LSA, defined as a serum amylase concentration of < 60 IU/l, was observed in 25% of asymptomatic individuals [12]. LSA is also associated with metabolic syndrome (MetS), a cluster of cardiovascular risk factors, and diabetes [12,13]. However, obesity is thought to be the strongest predictor of LSA in the asymptomatic general population [12].

In the last two decades, there has been a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide, along with an obesity pandemic [14,15]. NAFLD often progresses to a more severe condition, non-alcoholic steatohepatitis (NASH), and increased hepatic fibrosis is a significant histological feature of advanced NASH. NAFLD is considered to be a hepatic manifestation of

1 MetS and insulin resistance [14-18], which suggests that NAFLD consists of a wide
2
3
4 spectrum of cardiometabolic diseases. It is also possible that NAFLD may reflect more
5
6
7 pronounced insulin resistance compared with MetS in certain clinical settings, including
8
9
10 in individuals without diabetes or obesity [17,19,20]. In this context, we hypothesised
11
12
13 that LSA may be associated with NAFLD independently of MetS, type 2 diabetes, and
14
15
16 even obesity. The aim of this study was to test this hypothesis and to investigate the
17
18
19 clinical relevance of LSA, which is often observed in clinical practice. Therefore, we
20
21
22 examined the associations among serum amylase, cardiometabolic risk factors, NAFLD,
23
24
25 hepatic fibrosis, MetS, and diabetes in a cross-sectional study of asymptomatic adults.
26
27
28
29
30

31 **METHODS**

32 **Protocol and subjects**

33
34 The present report represents a series of observational studies performed in
35
36
37 collaboration with Josai University, Sakado, Japan, and Social Insurance Omiya
38
39
40 General Hospital that have been conducted to elucidate the relationships between
41
42
43 lifestyle-related diseases and cardiometabolic risk factors. We recruited, at random,
44
45
46 2,472 asymptomatic subjects aged 30–79 years who underwent thorough annual
47
48
49 medical check-ups, in which the subjects underwent a more extensive array of clinical
50
51
52 tests than would be performed in routine check-ups, at the Social Insurance Omiya
53
54
55
56 General Hospital, Saitama, Japan, between April 2009 and March 2010. The protocol
57
58
59
60

1
2 was approved by The Ethics Committee of Josai University and the Council of the
3
4 Hospital, and informed consent was obtained from all participants.
5
6

7
8 The exclusion criteria and a flow chart summarizing subject disposition are shown
9
10 in *Supplemental Figure 1*. To exclude subjects with latent conditions likely to
11
12 adversely affect the results, we excluded those with C-reactive protein ≥ 10.0 mg/l,
13
14 estimated glomerular filtration rate (eGFR) ≤ 35 ml/min/1.73 m², serum amylase ≤ 30
15
16 IU/l (the lower 5th percentile in an earlier study [12]) or ≥ 200 IU/l based on previous
17
18 reports [21,22], as well as subjects suspected of having cancer. In the current analysis,
19
20 to investigate the potential relationship between serum amylase and cardiometabolic
21
22 features, including NAFLD, we included subjects with a wider range of serum amylase
23
24 levels than the current reference ranges.
25
26
27
28
29
30
31
32

33
34 Subjects completed a questionnaire recording lifestyle factors, including habitual
35
36 alcohol consumption, which was classified in terms of the frequency (none, occasional,
37
38 and daily) and the amount of ethanol consumed per day (< 20 g, 20–39 g, 40–59 g, or \geq
39
40 60 g). Subjects who habitually consumed ≥ 20 g ethanol per day were excluded from the
41
42 study. Subjects positive for hepatic B virus surface antigen were also excluded. Hepatic
43
44 C virus infection was not measured in this study. We also excluded subjects with other
45
46 active liver diseases not examined, by excluded those with elevated serum liver enzyme
47
48 levels (approximately three times the upper limit of normal): alanine aminotransferase
49
50 (ALT) ≥ 150 IU/ml, aspartate aminotransferase (AST) ≥ 150 IU/ml, or
51
52
53
54
55
56
57
58
59
60

1 γ -glutamyltransferase (GGT) \geq 150 IU/ml. Consequently, a total of 1,475 individuals
2
3
4 were included in this study.
5
6
7
8
9

10 **Laboratory measurements**

11
12 Laboratory and anthropometric tests, and an abdominal ultrasound were performed in
13
14 the early morning after an overnight fast. Serum parameters were measured using an
15
16 AutoAnalyzer (Hitachi, Tokyo, Japan). The serum amylase level was measured using an
17
18 enzymatic method (L-type Amylase; Wako, Tokyo, Japan) with a detection limit of 1.7
19
20 IU/l, and a run-to-run coefficient of variation of < 5.0%.
21
22
23
24
25
26
27

28 Abdominal ultrasound for the detection of fatty liver was carried out by registered
29
30 medical sonographers who only work at Social Insurance Omiya General Hospital. The
31
32 sonographers were blinded to the subjects' data. Fatty liver, which was determined by
33
34 comparing liver echogenicity with that of the renal cortex [23], was defined as NAFLD.
35
36 Additionally, the severity of NAFLD was graded into three categories: mild NAFLD, a
37
38 slight increase in liver echogenicity with normal visualisation of the diaphragm and the
39
40 portal veins; moderate NAFLD, a moderate increase in liver echogenicity with slightly
41
42 impaired visualisation of the diaphragm and the portal veins; and severe NAFLD, a
43
44 substantial increase in liver echogenicity with poor or no visualisation of the diaphragm
45
46 and the portal veins [24,25]. In a previous study, the ultrasonographic steatosis score
47
48 determined using these grades was highly correlated with the histological grade of
49
50
51
52
53
54
55
56
57
58
59
60

1 steatosis ($r = 0.80$, $P < 0.001$), but not with inflammatory activity ($r = 0.10$) or fibrosis
2
3
4 score ($r = 0.19$) [25]. Therefore, the grade of NAFLD in this study probably reflects
5
6
7 overall hepatic fat accumulation, rather than the severity of fibrosis. Since it is possible
8
9
10 that mild NAFLD could include a normal liver, we defined overt NAFLD as moderate
11
12
13 or severe NAFLD. We also examined the findings of gallstones, cholecystectomy, and
14
15
16 splenomegaly, which was defined as a spleen index (calculated as the long dimension \times
17
18
19 short dimension on splenotomogram) ≥ 30 [26,27].

20
21
22 The liver fibrosis scores, the AST/ALT ratio [28] and FIB-4 were calculated in all
23
24
25 patients, using a previously published formula:

$$26 \text{ FIB-4} = \text{age (years)} \times \text{AST/platelet count (} 10^9/\text{l)} \times \text{ALT}^{1/2} \text{ [29]}$$

27
28
29
30 The diagnosis of MetS was based on the Adult Treatment Panel-III criteria [30]
31
32
33 with the following cut-off limits: 1) systolic blood pressure ≥ 130 mmHg or diastolic
34
35
36 blood pressure ≥ 85 mmHg; 2) triglyceride ≥ 150 mg/dl; 3) high-density
37
38
39 lipoprotein-cholesterol < 40 mg/dl for men and < 50 mg/dl for women; 4) fasting
40
41
42 plasma glucose ≥ 100 mg/dl; and 5) waist circumference ≥ 90 cm for men and ≥ 80 cm
43
44
45 for women. Subjects meeting three or more of these criteria, including treatment for any
46
47
48 of these disorders, were defined as having MetS. Diabetes was defined as fasting plasma
49
50
51 glucose ≥ 126 mg/dl or glycosylated haemoglobin (HbA1c) $\geq 6.5\%$ (by the National
52
53
54 Glycoprotein Standardization Program (NGSP)) according to the American Diabetes
55
56
57 Association criteria [31], or treatment with oral hypoglycaemic drugs or insulin. HbA1c
58
59
60

1 (Japan Diabetes Society [JDS]) was converted to HbA1c (NGSP) units using the
2
3
4
5 officially certified formula: $\text{HbA1c (NGSP) (\%)} = 1.02 \times \text{JDS (\%)} + 0.25\%$ [32].
6

7
8 Since serum amylase can be affected by kidney function because of its excretion
9
10 by the kidney [4,5], eGFR was considered as a confounding factor and was calculated
11
12 using the following equation for Japanese subjects [33]: $\text{eGFR (ml/min/1.73 m}^2\text{)} = 194$
13
14 $\times \text{serum Cr}^{-1.094} \times \text{age}^{-0.287}$ (if female) $\times 0.739$. Here, Cr = serum creatinine
15
16
17
18
19 concentration (mg/dl).
20
21
22
23
24

25 **Statistical analysis**

26
27 Data are expressed as the mean \pm standard deviation (SD) or median (interquartile
28
29 range). Subjects were divided into quartiles according to serum amylase levels, where
30
31 Q1 is the highest quartile and Q4 is the lowest quartile. *P*-values for continuous
32
33 variables were determined using analysis of variance (ANOVA) or the Mann-Whitney
34
35 *U* test, and for categorical variables using the χ^2 test. Highly skewed values (ALT, AST,
36
37 GGT, and triglyceride) were log-transformed before analysis. Subjects were also
38
39 stratified into four groups according to the grade of NAFLD (i.e., normal, mild,
40
41 moderate, and severe NAFLD). Multivariate logistic regression models were used to
42
43 examine the associations of quartiles (Q2–4) of serum amylase with any-grade NAFLD
44
45 (NAFLD-AG), and with overt NAFLD relative to Q1, controlling for relevant
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 confounding factors, including MetS, diabetes, and body mass index (BMI) or waist

1 circumference (WC). To elucidate any association between LSA and NAFLD, we
2
3
4 examined the associations between LSA and NAFLD-AG, and between LSA and overt
5
6
7 NAFLD. This analysis yielded odds ratios (OR) and 95% confidential intervals (95%
8
9
10 CI). Tests for linear trends (P for trend) were calculated by treating the quartiles as a
11
12
13 continuous variable (i.e., 1–4), and the same model analysis was conducted. Statistical
14
15
16 analyses were performed using SPSS software version 18.0 (SPSS-IBM, Chicago, IL,
17
18
19 USA) and Statview version 5.0 (SAS Institute, Cary, NC, USA). Values of $P < 0.05$
20
21
22 were considered to be statistically significant.
23
24
25
26
27

28 RESULTS

29
30 The clinical characteristics of the subjects according to the quartile of serum amylase
31
32 are shown in Table 1. The mean and median values of most clinical parameters,
33
34 including platelet count and eGFR, increased significantly as serum amylase decreased,
35
36
37 although there was a significant trend for subjects with lower amylase levels to be
38
39
40 younger. No significant trend in HbA1c was observed against quartiles of serum
41
42
43 amylase. The prevalence of NAFLD-AG and overt NAFLD increased significantly,
44
45
46 from 22.5% to 42.4% and from 9.2% to 24%, respectively, from the highest (Q1) to the
47
48
49 lowest serum amylase quartile (Q4). There were no significant differences in the
50
51
52 prevalence rates of gallstones, cholecystectomy, or splenomegaly between quartiles,
53
54
55 possibly because of the small numbers of subjects with these features, although the rates
56
57
58
59
60

1 of cholecystectomy and splenomegaly were higher in Q4 compared with the other
2
3
4 quartiles. Log-transformed serum ALT and GGT increased significantly, whereas the
5
6
7 AST/ALT ratio and FIB-4 decreased significantly with decreasing serum amylase
8
9
10 quartile.

11
12
13 When subjects were stratified according to NAFLD grade, serum amylase
14
15 decreased significantly with advancing grade of NAFLD (Figure 1). When subjects
16
17 were further stratified according to sex, there was no significant difference between men
18
19 and women. However, when the subjects were stratified according to high or low BMI
20
21 (Figure 2), serum amylase levels were significantly lower in overweight/obese subjects
22
23 (BMI ≥ 25.0 kg/m², mean \pm SD BMI, 27.3 \pm 2.3 kg/m², n = 1,121) than in lean subjects
24
25 (BMI < 25.0 kg/m², mean \pm SD BMI, 21.6 \pm 2.0 kg/m², n = 354). Serum amylase levels
26
27 in lean subjects decreased significantly with advancing grade of NAFLD, whereas those
28
29 in obese subjects did not. Significant differences between lean and obese subjects were
30
31 only observed in subjects with a normal liver or mild NAFLD. We did not conduct an
32
33 analysis by further stratification according to MetS or diabetes because of the small
34
35 proportion of subjects (both, < 10%).
36
37
38
39
40
41
42
43
44
45
46
47

48 Multiple logistic regression analysis showed that, compared with the highest
49
50 quartile of serum amylase (≥ 90 IU/l, Q1), the lowest quartile (< 60 IU/l, Q4) was
51
52 significantly associated with NAFLD-AG even after adjusting for confounders plus
53
54 MetS or diabetes (Table 2, Models 4 and 5). In these conditions, MetS (OR: 3.66, 95%
55
56
57
58
59
60

1
2 CI: 2.37–5.65) and diabetes (OR: 1.96, 95% CI: 1.25–3.05) were significantly
3
4 associated with Q4 of serum amylase (data not shown). However, these associations
5
6 were markedly attenuated and were no longer statistically significant after adjusting for
7
8 clinical confounders plus BMI or WC (Models 6 and 7), although there was a trend
9
10 towards an association among the quartiles of serum amylase.
11
12
13
14

15
16 When we excluded subjects with mild NAFLD (n = 242) and repeated the
17
18 analysis (Table 3), we detected stronger significant associations between Q4 and overt
19
20 NAFLD. These associations were also moderately attenuated after additional adjustment
21
22 for BMI or WC, but they remained statistically significant (Models 6 and 7). In this
23
24 condition, BMI (OR: 1.65, 95% CI: 1.51–1.80) and WC (OR: 1.21, 95% CI: 1.17–1.25)
25
26 were significantly associated with overt NAFLD (data not shown).
27
28
29
30
31
32
33
34
35

36 DISCUSSION

37
38 For the last few decades, NAFLD has been considered as a manifestation of MetS and
39
40 insulin resistance [14-18]. In this context, the present study showed that LSA was
41
42 significantly associated with NAFLD-AG in asymptomatic adults, independent of MetS,
43
44 diabetes, and sex. Furthermore, LSA may be indicative of overt NAFLD, i.e., moderate
45
46 or severe NAFLD, independent of obesity. These findings are not inconsistent because
47
48 NAFLD may reflect insulin resistance, more so than MetS, in individuals without
49
50 diabetes or obesity [17,19,20].
51
52
53
54
55
56
57
58
59
60

1
2 This study provided evidence that NAFLD can occur in lean individuals, who
3
4 accounted for 37.8% (62/104) of subjects with moderate NAFLD and 19.3% (11/57) of
5
6
7 subjects with severe NAFLD (Figure 2). This is consistent with the results of
8
9
10 multivariate logistic analysis, where there was a significant trend for NAFLD against
11
12
13 quartiles of serum amylase, and the significant association between the lowest quartile
14
15
16 of serum amylase and NAFLD remained after adjusting for BMI and WC (Tables 2 and
17
18
19 3).

20
21
22
23
24
25 ***Potential mechanisms of the inverse relationship between serum amylase and***
26
27
28 ***NAFLD***

29
30 We found no significant difference in serum amylase levels between lean and obese
31
32 subjects with overt NAFLD, suggesting that the effects of obesity on serum amylase are
33
34 apparent in subjects with a normal liver or with mild NAFLD, but not in subjects with
35
36
37 overt NAFLD. Several studies have shown that NAFLD occurs in non-obese people,
38
39
40 although the prevalence of NAFLD in non-obese subjects is lower than that in obese
41
42
43 subjects [19,20,34]. Therefore, other than obesity, factors not examined in this study
44
45
46 might also explain the association between LSA and NAFLD. Insulin resistance and
47
48
49 obesity-related hormones, such as leptin, may be potential factors, because insulin
50
51
52 resistance and energy imbalance are common pathophysiological findings in obese
53
54
55 individuals [17,35]. Indeed, obesity plus insulin resistance is more closely associated
56
57
58
59
60

1 with metabolic abnormalities and NAFLD than is obesity without insulin resistance [17].
2
3
4 Hyperinsulinaemia caused by insulin resistance stimulates *de novo* lipogenesis in the
5
6
7 liver through sterol regulatory element binding protein-1c (SREBP-1c) [36],
8
9
10 irrespective of the influx of fatty acid from a meal and lipolysis in adipose tissues.
11
12
13 Additionally, we recently reported a latent association between LSA and insulin
14
15
16 resistance in a small study of asymptomatic middle-aged adults [37], supporting the
17
18
19 hypothesis that LSA may be associated with NAFLD, at least in part through insulin
20
21
22 resistance. However, because insulin resistance, as determined by the homeostasis
23
24
25 model assessment of insulin resistance for example, was not examined in this study,
26
27
28 further large epidemiological studies evaluating insulin resistance are needed to confirm
29
30
31 the current hypothesis.
32

33
34 As another explanation for the inverse relationship between serum amylase and
35
36
37 NAFLD, systemic ectopic fat deposition in organs including the pancreas (i.e., fatty
38
39
40 pancreas) might contribute to the observed associations. This is because intrapancreatic
41
42
43 fat, particularly intralobular pancreatic fat, was reported to be associated with NAFLD
44
45
46 and MetS [38,39]. An animal study showed that obese mice had a heavier pancreas and
47
48
49 more intrapancreatic fat [40]. Therefore, systemic fat deposits in multiple organs may be
50
51
52 a common cause underlying the association between NAFLD and overall pancreatic
53
54
55 dysfunction, which may result in impaired exocrine function, characterised as LSA.
56

57 Gene polymorphisms of patatin-like phospholipase domain containing 3
58
59
60

1 (PNPLA3) may also contribute to the strength of these associations. For example, a
2
3
4 common variant of the PNPLA3 gene (rs738409) was reported to be associated with
5
6
7 increased hepatic fat content (i.e., NAFLD) [41]. In the mouse liver,
8
9
10 adiponutrin/PNPLA3 gene expression is under the direct transcriptional control of
11
12
13 SREBP-1c, in response to insulin [42].
14
15
16
17
18

19 *Serum amyalse and glucose metabolism*

20
21 The prevalence of diabetes increased with decreasing serum amylase quartile in this
22
23 study. However, similar to an earlier study [12], HbA1c was not associated with LSA,
24
25 probably because most subjects in the lowest quartile of serum amylase in this study
26
27
28 had no or only mild insulin resistance or mild hyperinsulinaemia, which is likely
29
30
31 compensated for and results in euglycaemia or mild hyperglycaemia. In such conditions,
32
33
34 fasting plasma glucose would increase linearly, as observed in Table 1, in response to
35
36
37 insulin resistance, particularly in the early stage of diabetes [43,44].
38
39
40
41
42
43
44

45 *Serum amyalse and hepatic fibrosis*

46
47 To date, some markers have been considered for screening for NAFLD and mild hepatic
48
49 fibrosis [45-47]. In this study, while the AST/ALT ratio and Fib-4 decreased
50
51
52 significantly with the decreasing quartile of serum amylase, the platelet count increased
53
54
55
56 (Table 1). Consequently, hepatic fibrosis is unlikely to be associated with NAFLD in
57
58
59
60

1 this study. A plausible explanation is that this study mostly consisted of non-obese
2
3 individuals, with a small proportion having MetS and diabetes, resulting in a lower
4
5 likelihood of advanced hepatic fibrosis and NASH. In fact, the estimated prevalence of
6
7 NASH in this study is quite low when we compare it with the prevalence of NASH in a
8
9 nationwide study in Japan. It was reported that approximately 20–25% of patients with
10
11 diabetes had NAFLD, a population in which the prevalence of NASH might be 30–40%
12
13 [48]. Therefore, the estimated prevalence of NASH might be less than 1% of all of the
14
15 subjects in this study. In addition, the fact that more than half of the subjects in this
16
17 study had repeatedly undergone detailed medical check-ups may also contribute to the
18
19 lower prevalence of NASH, because repeated check-ups may promote consciousness of
20
21 healthcare and favourable lifestyles.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Limitations**

38
39 Several limitations should be mentioned. First, NAFLD was diagnosed by ultrasound
40
41 rather than by histological examination, the gold standard technique for the diagnosis of
42
43 NAFLD. Thus, NAFLD and the degree of hepatic fibrosis could be inaccurately
44
45 evaluated, particularly in the early stages. In earlier studies, ultrasonography had a
46
47 sensitivity of 60–94% and a specificity of 66–95% for detecting fatty liver [24,49].
48
49
50
51 However, its sensitivity is reduced in subjects with a small amount of fat (< 30%), such
52
53
54
55
56
57
58
59
60 as those with mild NAFLD or advanced fibrosis, [14]. To improve the accuracy of

1 detecting and grading of NAFLD, the use of other imaging modalities might be needed,
2
3
4 such as magnetic resonance imaging and magnetic resonance spectroscopy, which were
5
6
7 reported to provide useful quantitative data in earlier studies [50,51].
8
9

10 Second, hepatitis C virus infection was not measured in this study. However, the
11
12 prevalence of hepatitis C infection was reported to be 1.5–2.3% in Japan [52]. Low
13
14 prevalence rates of hepatitis C (< 1.5%) were also recently reported in Asian-Pacific,
15
16 tropical Latin American, and North American countries [53]. Therefore, hepatitis C
17
18 infection is unlikely to profoundly modify the association between LSA and NAFLD in
19
20 this study, although hepatitis C infection can contribute to the development of NAFLD
21
22 [54]. It is also possible that individuals with primary biliary cirrhosis, autoimmune
23
24 hepatitis or other forms of liver dysfunction (e.g., haemochromatosis and Wilson
25
26 disease) were included in the present study, even though we excluded subjects with
27
28 elevated hepatic enzymes (≥ 150 IU/ml). However, the prevalence of these diseases is
29
30 quite low in the general population [55-57].
31
32
33
34
35
36
37
38
39
40
41

42 Third, because of the cross-sectional nature of the study, we could not determine
43
44 the cause–effect relationship between LSA and NAFLD. However, in a previous
45
46 retrospective study [12], subjects with LSA at baseline were more likely to develop
47
48 MetS-related metabolic abnormalities 5 years later. Longitudinal prospective studies or
49
50 clinical intervention trials are needed to elucidate the causality of the associations
51
52
53
54 reported here.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Finally, the clinical relevance of measuring serum amylase remains unclear. The current results suggest that LSA is likely to detect overt NAFLD, but not NASH, which is the most important hepatic disorder. However, from the cardiometabolic perspective, even simple steatosis may be important, particularly in nonobese people, because steatosis may be more strongly associated with insulin resistance than is obesity [17,19,20]. Currently, serum amylase is rarely considered in clinical practice, except in certain situations, such as suspected pancreatitis. Therefore, numerous clinical and animal studies are needed to validate and confirm the clinical relevance of measuring serum amylase before it can be introduced into primary care for the detection of cardiometabolic diseases and NAFLD.

Conclusion

Our results suggest that LSA may be associated with NAFLD, particularly moderate or severe NAFLD, in asymptomatic adults. This association was independent of MetS, diabetes, and obesity. Further studies are needed to confirm the observed associations, and to explore the clinical relevance of LSA.

Acknowledgments None

1
2 **Competing interests** The authors declare that they have no competing interests.
3
4
5
6

7 **Funding** This research received no specific grant from any funding agency in the public,
8
9 commercial, or not-for-profit sectors.
10
11
12

13
14
15
16 **Contributors** KN, HM, and MK designed the collaborative project; KN, HO, TM, and
17
18 HF collected and analysed the data; KN, HO, MS, and YH researched and evaluated the
19
20 literature; and KN wrote the first draft of the manuscript. All authors reviewed and
21
22 edited the manuscript, and approved the final version of the manuscript.
23
24
25
26
27
28
29
30

31 **Data sharing statement** There are no additional data available.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Yegneswaran B, Pitchumoni CS. Yegneswaran B, et al. When should serum amylase and lipase levels be repeated in a patient with acute pancreatitis? *Cleve Clin J Med* 2010;77:230–1.
2. Skrha J, Stěpán J. Clinical significance of amylase isoenzyme determination. *Acta Univ Carol Med Monogr* 1987;120:1–81.
3. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? *Gastroenterol Clin North Am* 1990;19:793–810.
4. Junge W, Mályusz M, Ehrens HJ. The role of the kidney in the elimination of pancreatic lipase and amylase from blood. *J Clin Chem Clin Biochem* 1985;23:387–92.
5. Collen MJ, Ansher AF, Chapman AB, et al. Serum amylase in patients with renal insufficiency and renal failure. *Am J Gastroenterol* 1990;85:1377–80.
6. Domínguez-Muñoz JE, Pieramico O, Büchler M, et al. Ratios of different serum pancreatic enzymes in the diagnosis and staging of chronic pancreatitis. *Digestion* 1993;54:231–6.
7. Wolf RO, Hubbard VS, Gillard BK, et al. Three methods compared for determination of pancreatic and salivary amylase activity in serum of cystic fibrosis patients. *Clin Chem* 1986;32:296–300.
8. Frier BM, Faber OK, Binder C, et al. The effect of residual insulin secretion on

- 1
2 exocrine pancreatic function in juvenile-onset diabetes mellitus. *Diabetologia*
3
4
5 1978;14:301–4.
6
7
8 9. Dandona P, Freedman DB, Foo Y, et al. Exocrine pancreatic function in diabetes
9
10 mellitus. *J Clin Pathol* 1984;37:302–6
11
12
13 10. Swislocki A, Noth R, Hallstone A, et al. Secretin-stimulated amylase release into
14
15 blood is impaired in type 1 diabetes mellitus. *Horm Metab Res* 2005;37:326–330.
16
17
18 11. Aughsteen AA, Abu-Umair MS, Mahmoud SA. Biochemical analysis of serum
19
20 pancreatic amylase and lipase enzymes in patients with type 1 and type 2 diabetes
21
22 mellitus. *Saudi Med J* 2005;26:73–7.
23
24
25
26
27 12. Nakajima K, Nemoto T, Muneyuki T, et al. Low serum amylase in association with
28
29 metabolic syndrome and diabetes: A community-based study. *Cardiovasc Diabetol*
30
31 2011;10:34.
32
33
34
35
36 13. Lee JG, Park SW, Cho BM, et al. Serum amylase and risk of the metabolic
37
38 syndrome in Korean adults. *Clin Chim Acta* 2011; 412:1848–53
39
40
41
42 14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of
43
44 an AASLD Single Topic Conference. *Hepatology* 2003;37:1202–19.
45
46
47
48 15. Smith BW, Adams LA. Non-alcoholic fatty liver disease. *Crit Rev Clin Lab Sci*
49
50 2011;48:97–113.
51
52
53
54 16. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. *Diabetes*
55
56 2011;60:2011–7.
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med* 2008;168:1609–16.
 18. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. *J Clin Endocrinol Metab* 2005; 90:1578–82.
 19. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. *Arch Intern Med* 2004;164:2169–75.
 20. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. *Diabetes Care* 2008;31:562–8.
 21. Keogh JB, McGeeney KF, Drury MI, et al. Renal clearance of pancreatic and salivary amylase relative to creatinine in patients with chronic renal insufficiency. *Gut* 1978;19:1125–30.
 22. Okura Y, Hayashi K, Shingu T, et al. Diagnostic evaluation of acute pancreatitis in two patients with hypertriglyceridemia. *World J Gastroenterol* 2004;10:3691–5.
 23. Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. *J Ultrasound Med* 2002;21:1023–32.
 24. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. *J Hepatol* 2009;51:433–45.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Shannon A, Alkhoury N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. *J Pediatr Gastroenterol Nutr* 2011;53:190–5.
 26. Ishibashi H, Higuchi N, Shimamura R, et al. Sonographic assessment and grading of spleen size. *J Clin Ultrasound* 1991;19:21–5.
 27. Kataoka M, Nakata Y, Maeda T, et al. Ultrasonographic analysis of splenomegaly in patients with sarcoidosis. *Nihon Kyobu Shikkan Gakkai Zasshi* 1990;28:750–5. [In Japanese]
 28. Iacobellis A, Marcellini M, Andriulli A, et al. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. *World J Gastroenterol* 2006;12:7821–5.
 29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. *Hepatology* 2007;46:32–6.
 30. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735–52.
 31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010;33 Suppl 1:S62–9.
 32. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National

- 1
2 Glycohemoglobin Standardization Program values. *J Diabetes Investig*
3
4
5 2012;3:39–40.
6
7
8 33. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum
9
10 creatinine in Japan. *Am J Kidney Dis* 2009;53:982–92.
11
12
13 34. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country
14
15 has a high prevalence of nonalcoholic fatty liver and significant liver disease.
16
17
18
19
20
21
22
23 35. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy
24
25 balance. *J Clin Invest* 2011;121:2087–93.
26
27
28 36. Dentin R, Pégrier JP, Benhamed F, et al. Hepatic glucokinase is required for the
29
30 synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene
31
32 expression. *J Biol Chem* 2004;279:20314–26.
33
34
35
36 37. Muneyuki T, Nakajima K, Aoki A, et al. Latent associations of low serum amylase
37
38 with decreased plasma insulin levels and insulin resistance in asymptomatic
39
40 middle-aged adults. *Cardiovasc Diabetol* 2012;11:80.
41
42
43
44
45 38. van Geenen EJ, Smits MM, Schreuder TC, et al. Nonalcoholic fatty liver disease is
46
47 related to nonalcoholic fatty pancreas disease. *Pancreas* 2010;39:1185–90.
48
49
50
51 39. Sepe PS, Ohri A, Sanaka S, et al. A prospective evaluation of fatty pancreas by
52
53 using EUS. *Gastrointest Endosc* 2011;73:987–93.
54
55
56
57 40. Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. *HPB*
58
59
60

- 1
2 (Oxford) 2007;9:312–8.
3
4
5 41. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of
6
7 patatin-like phospholipase domain containing 3 gene (PNPLA3) on the
8
9 susceptibility and histological severity of nonalcoholic fatty liver disease.
10
11
12
13 *Hepatology* 2011;53:1883–94.
14
15
16 42. Dubuquoy C, Robichon C, Lasnier F, et al. Distinct regulation of
17
18 adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and
19
20
21
22 SREBP1c in mouse and human hepatocytes. *J Hepatol* 2011;55:145–53.
23
24
25 43. Reaven G. Wanted!: a standardized measurement of plasma insulin concentration.
26
27
28 *Arterioscler Thromb Vasc Biol* 2011;31:954–55.
29
30
31 44. Robins SJ, Lyass A, Zachariah JP, et al. Insulin resistance and the relationship of a
32
33
34 dyslipidemia to coronary heart disease: the Framingham Heart Study. *Arterioscler*
35
36
37 *Thromb Vasc Biol* 2011;31:1208–14.
38
39
40 45. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase
41
42
43 in chronic hepatitis. Relationship to cirrhosis. *Gastroenterology* 1988;95:734–9.
44
45
46 46. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive
47
48
49 system that identifies liver fibrosis in patients with NAFLD. *Hepatology*
50
51
52 2007;45:846–54.
53
54
55 47. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring
56
57
58 systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty
59
60

- 1
2 liver disease. *Gut* 2010;59:1265–9.
3
4
5 48. Okanoue T, Umemura A, Yasui K, et al. Nonalcoholic fatty liver disease and
6
7 nonalcoholic steatohepatitis in Japan. *J Gastroenterol Hepatol* 2011;26 Suppl
8
9 1:153–62.
10
11
12
13 49. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with
14
15 ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol*
16
17 1991;43:26–31.
18
19
20
21
22 50. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and
23
24 quantification of liver steatosis by ultrasound, computed tomography and magnetic
25
26 resonance. *J Hepatol* 2009;51:433–45.
27
28
29
30
31 51. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver
32
33 disease and advanced fibrosis in Hong Kong Chinese: a population study using
34
35 proton-magnetic resonance spectroscopy and transient elastography. *Gut*
36
37 2012;61:409–15.
38
39
40
41
42 52. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus
43
44 infection. *Lancet Infect Dis* 2005;5:558–67.
45
46
47
48 53. Hanafiah KM, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C
49
50 virus infection: New estimates of age-specific antibody to hepatitis C virus
51
52 seroprevalence. *Hepatology* 2012 Nov 21.
53
54
55
56
57 54. Pattullo V, Douglas MW, George J. Organelle dysfunction in hepatitis C
58
59
60

1 virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?
2
3

4 *Expert Rev Gastroenterol Hepatol* 2011;5:265–77.
5
6

7 55. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. *Orphanet J Rare Dis* 2008;3:1.
8
9

10 56. Strassburg CP. Autoimmune hepatitis. *Best Pract Res Clin Gastroenterol*
11
12

13 2010;24:667–82.
14
15

16 57. Oh RC, Husted TR. Causes and evaluation of mildly elevated liver transaminase
17
18

19 levels. *Am Fam Physician* 2011;84:1003–8.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1 Serum amylase levels according to the grade of NAFLD and sex. Serum amylase levels decreased significantly with advancing grade of NAFLD in both sexes (ANOVA, both $P = 0.0001$). There was no significant difference between men and women (two-way ANOVA, $P = 0.45$). *Number of subjects in each group. Bars represent standard errors.

Figure 2 Serum amylase levels according to the grade of NAFLD and obesity. Obesity was defined as $BMI \geq 25.0 \text{ kg/m}^2$. Serum amylase levels decreased significantly with advancing grade of NAFLD in lean subjects (ANOVA, $P = 0.01$), but not in obese subjects ($P = 0.33$). An overall significant difference was observed between lean and obese subjects (two-way ANOVA, $P = 0.03$). *Number of subjects in each group; † $P = 0.0001$ and ‡ $P = 0.02$ for lean versus obese subjects (Mann–Whitney U test). Bars represent standard errors.

Supplement Figure 1

Exclusion criteria of subjects and flow chart

Table 1. Characteristics of subjects stratified according to quartiles of serum amylase

	Total	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> value
n	1,475	369	371	381	354	
Age, y	55.1 ± 12.2	58.4 ± 11.8	56.4 ± 12.2	52.9 ± 11.7	52.7 ± 12.0	< 0.0001
Men, n (%)	747 (50.6)	178 (48.2)	176 (47.4)	205 (53.8)	188 (53.1)	0.19
BMI, kg/m ²	23.0 ± 3.2	21.9 ± 2.7	22.6 ± 3.2	23.3 ± 3.1	24.1 ± 3.4	< 0.0001
WC, cm	80.8 ± 8.9	78.2 ± 8.3	79.9 ± 8.8	81.8 ± 8.8	83.2 ± 9.1	< 0.0001
Systolic blood pressure, mmHg	120 ± 18.9	119 ± 18.5	119 ± 18.7	120 ± 18.9	123 ± 19.1	0.007
Diastolic blood pressure, mmHg	74.1 ± 12.6	72.6 ± 12.2	73.1 ± 11.9	74.5 ± 13.4	76.1 ± 12.4	0.0009
Platelet count, 10 ⁹ /L	235 ± 53.4	228 ± 53.8	235 ± 53.1	237 ± 51.1	241 ± 55.2	0.01
ALT, IU/l	18 (14–25)	18 (14–23)	17 (14–23)	18 (14–25)	19 (14–29)	< 0.0001
AST, IU/l	20 (17–24)	21 (19–25)	20 (17–24)	19 (17–23)	20 (17–24)	0.04
AST/ALT	1.15 ± 0.36	1.24 ± 0.35	1.20 ± 0.37	1.12 ± 0.33	1.04 ± 0.35	< 0.0001

FIB-4	1.13 (0.82–1.52)	1.33 (0.98–1.76)	1.20 (0.89–1.59)	1.05 (0.76–1.38)	0.98 (0.70–1.36)	< 0.0001
GGT, IU/l	22 (16–33)	20 (15–31)	20 (16–30)	23 (16–34)	24 (17–38)	0.0009
C-reactive protein	0.4 (0.3–0.8)	0.3 (0.3–0.63)	0.4 (0.3–0.8)	0.4 (0.3–0.8)	0.5 (0.3–1.1)	< 0.0001
Amylase, IU/l	77.3 ± 24.9	110 ± 22.0	81.3 ± 4.7	66.6 ± 4.1	50.3 ± 7.0	—
(range)	(30–200)	(90–200)	(74–89)	(60–73)	(30–59)	
Triglyceride, mg/dl	88 (64–128)	83 (63–121)	84 (62–123)	88 (65–128)	100 (65–143)	0.001
HDL-cholesterol, mg/dl	61.2 ± 15.0	64.2 ± 15.4	62.6 ± 14.8	59.8 ± 14.6	58.3 ± 14.5	< 0.0001
Fasting plasma glucose, mg/dl	99.6 ± 16.7	97.5 ± 13.4	97.4 ± 11.4	101 ± 19.4	103 ± 20.4	< 0.0001
HbA1c (NGSP), %	5.7 ± 0.6	5.7 ± 0.5	5.7 ± 0.4	5.7 ± 0.6	5.8 ± 0.7	0.14
eGFR, ml/min/1.73m ²	75.0 ± 13.9	71.0 ± 14.3	74.3 ± 12.9	76.0 ± 14.2	78.7 ± 13.1	< 0.0001
ATP-III-Metabolic syndrome, n (%)	139 (9.4)	16 (4.3)	23 (6.2)	47 (12.3)	53 (15.0)	< 0.0001
Diabetes, n (%)	114 (7.7)	19 (5.1)	17 (4.6)	34 (8.9)	44 (12.4)	0.0002
NAFLD of all grades, n (%)	463 (31.4)	83 (22.5)	97 (26.1)	133 (34.9)	150 (42.4)	< 0.0001

Moderate to severe NAFLD, n (%)	221 (15.0)	34 (9.2)	42 (11.3)	60 (15.7)	85 (24.0)	< 0.0001
Gallstones, n (%)	81 (5.5)	21 (5.7)	20 (5.4)	24 (6.3)	16 (5.2)	0.76
Cholecystectomy, n (%)	23 (1.6)	5 (1.4)	3 (0.8)	5 (1.3)	10 (2.8)	0.15
Splenomegaly, n (%)	9 (0.6)	1 (0.3)	1 (0.3)	0	7 (2.0)	—*
Medical history of						
Cardiovascular diseases, n (%)	55 (3.7)	11 (3.0)	20 (5.4)	11 (2.9)	13 (3.7)	0.24
Stroke, n (%)	26 (1.8)	12 (3.3)	6 (1.6)	4 (1.1)	4 (1.1)	0.08
Medications for						
Hypertension, n (%)	237 (16.1)	64 (17.3)	47 (12.7)	67 (17.6)	59 (16.7)	0.22
Hypercholesterolemia, n (%)	177 (12.0)	56 (15.2)	43 (11.6)	34 (8.9)	44 (12.4)	0.07
Diabetes, n (%)	56 (3.8)	12 (3.3)	12 (3.2)	15 (3.9)	17 (4.8)	0.65
Current smoker, n (%)	273 (18.5)	40 (10.8)	50 (13.5)	86 (22.6)	97 (27.4)	< 0.0001
Everyday alcohol consumers, n (%)	229 (15.5)	51 (13.8)	59 (15.9)	66 (17.3)	53 (15.0)	0.61

Regular exercise, n (%)	507 (34.4)	144 (39.0)	135 (36.4)	125 (32.9)	103 (29.1)	0.03
-------------------------	------------	------------	------------	------------	------------	------

Data are means \pm SD and medians (interquartile range). *P*-values for continuous variables and categorical variables were determined by analysis of variance and the χ^2

test, respectively. Regular exercise: ≥ 30 min exercise per session at least twice a week.

*Statistical analysis was not performed because of the small number of subjects with splenomegaly.

Table 2. Odds ratios for NAFLD-AG according to serum amylase quartiles

Serum amylase quartiles	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> for trend
n	369	371	381	354	
Model 1	1	1.22 (0.87–1.71)	1.85 (1.34–2.55)	2.53 (1.84–3.50)	< 0.0001
Model 2	1	1.28 (0.91–1.81)	1.96 (1.39–2.74)	2.74 (1.95–3.85)	< 0.0001
Model 3	1	1.35 (0.93–1.97)	2.03 (1.41–2.94)	2.41 (1.66–3.51)	< 0.0001
Model 4	1	1.25 (0.86–1.82)	1.83 (1.26–2.65)	2.18 (1.49–3.18)	< 0.0001
Model 5	1	1.31 (0.90–1.90)	2.00 (1.39–2.89)	2.36 (1.62–3.44)	< 0.0001
Model 6	1	0.99 (0.66–1.49)	1.34 (0.89–2.01)	1.42 (0.94–2.15)	0.04
Model 7	1	1.02 (0.68–1.53)	1.30 (0.87–1.94)	1.49 (0.99–2.24)	0.03

Model 1: unadjusted.

Model 2: adjusted for age, sex, and current smoking (*versus* non-smokers).

Model 3: Model 2 plus adjustment for log-transformed ALT, regular exercise (*versus* infrequent exercise), daily alcohol consumption (*versus* infrequent/no alcohol)

1
2
3
4 consumption), eGFR, past history of heart diseases and stroke, and medications for hypertension, diabetes, and dyslipidemia.
5
6

7 Model 4: Model 3 plus adjustment for diabetes, but excluding medications for hypertension, diabetes, and dyslipidemia.
8
9

10 Model 5: Model 3 plus adjustment for metabolic syndrome, but excluding medications for hypertension, diabetes, and dyslipidemia.
11
12

13 Model 6: Model 3 plus adjustment for BMI.
14
15

16 Model 7: Model 3 plus adjustment for WC.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

Table 3. Odds ratios of each serum amylase for NAFLD of moderate or severe grade

Serum amylase quartiles	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> for trend
N*	320	316	308	289	
Model 1	1	1.29 (0.80–2.09)	2.04 (1.29–3.20)	3.51 (2.27–5.42)	< 0.0001
Model 2	1	1.36 (0.83–2.22)	2.14 (1.33–3.44)	3.81 (2.40–6.05)	< 0.0001
Model 3	1	1.61 (0.91–2.86)	2.32 (1.32–4.07)	3.45 (1.99–6.00)	< 0.0001
Model 4	1	1.48 (0.84–2.64)	2.11 (1.19–3.73)	2.97 (1.70–5.20)	< 0.0001
Model 5	1	1.56 (0.89–2.75)	2.32 (1.33–4.04)	3.26 (1.88–5.66)	< 0.0001
Model 6	1	1.05 (0.54–2.03)	1.44 (0.76–2.72)	2.01 (1.07–3.78)	0.01
Model 7	1	1.06 (0.55–2.05)	1.37 (0.73–2.59)	2.06 (1.09–3.87)	0.01

*Subjects with mild NAFLD (n = 242) were excluded from this analysis. Models 1–7 are the same as those in **Table 2**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Independent association between low serum amylase and non-alcoholic fatty liver disease in asymptomatic adults: A cross-sectional observational study

Short title: Low serum amylase and non-alcoholic fatty liver disease

Kei Nakajima^{1,4*}, Haruki Oshida¹ Toshitaka Muneyuki,² Masafumi Saito,¹ Yumiko Hori,¹ Hiroshi Fuchugami,³ Masafumi Kakei², Hiromi Munakata⁴

*Correspondence to Kei Nakajima, M.D., Ph.D., Division of Clinical Nutrition,
Department of Medical Dietetics, Faculty of Pharmaceutical Sciences, Josai University,
1-1 Keyakidai, Sakado, Saitama, 350-0295, Japan
email: keinaka@josai.ac.jp; Tel: +81-49-271-7260; Fax: +81-49-271-7260

1 Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of
Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295,
Japan

2 First Department of Comprehensive Medicine, Saitama Medical Center, Jichi Medical
University School of Medicine, 1-847 Amanuma, Omiya, Saitama 330-8503, Japan

3 Department of Health Care Center, Social Insurance Omiya General Hospital, 453
Bonsai, Kita, Saitama 331-0805, Japan

1
2 4 Department of Internal Medicine, Social Insurance Omiya General Hospital, 453
3

4
5 Bonsai, Kita, Saitama 331-0805, Japan
6
7
8
9

10 **Key words:** serum amylase, NAFLD, metabolic syndrome, diabetes
11

12
13 **Word count:** 3334 words
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT

Objectives: Low serum amylase (LSA) was reported to be associated with obesity, metabolic syndrome (MetS), and diabetes. However, it is unknown whether LSA is associated with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of MetS and insulin resistance. Therefore, we performed a clinical epidemiological study to investigate this potential association.

Design: A cross-sectional observational study with multivariate analysis.

Setting: Subjects were recruited in a healthcare centre in Saitama, an eastern district of Japan, near Tokyo.

Participants: A total of 1,475 asymptomatic adults aged 30–79 years who underwent detailed medical check-ups and who regularly consumed small amounts of alcohol (< 20 g/day).

Outcome measures: Serum amylase, cardiometabolic risk factors, NAFLD determined by ultrasound, MetS determined by Adult Treatment Panel-III criteria, and diabetes were assessed.

Results: The prevalence of NAFLD increased significantly from 22.5% to 42.4% (all grades) and from 9.2% to 24.0% (moderate or severe grade) from the highest to the lowest quartile of serum amylase. Multiple logistic regression analysis showed that, compared with the highest quartile of serum amylase, the lowest quartile of serum amylase was significantly associated with any-grade NAFLD and with moderate to

1 severe NAFLD, even after adjusting for MetS or diabetes. The association between LSA
2
3
4 and any-grade NAFLD disappeared after further adjustment for body mass index or
5
6
7 waist circumference, whereas the association between LSA and moderate or severe
8
9
10 NAFLD remained statistically significant [odds ratios (95% confidence interval), 2.01
11
12
13 (1.07–3.78) and 2.06 (1.09–3.87), respectively, both $P = 0.01$].
14
15

16 **Conclusions:** Our results suggest that LSA may be associated with moderate or severe
17
18
19 NAFLD in asymptomatic adults independent of MetS, diabetes, and obesity. These
20
21
22 results warrant confirmation in further studies.
23

24 (274/300 words)
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- The clinical relevance of low serum amylase (LSA) is unclear, but it is putatively associated with obesity-related metabolic abnormalities.
- It is unknown whether LSA is associated with non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of cardiometabolic disease and insulin resistance.

Key messages

- Our results suggest that LSA is associated with NAFLD independent of metabolic syndrome, diabetes, and obesity.
- LSA may be an independent marker for moderate or severe NAFLD.

Strengths and limitations of this study

- A possible association between LSA and NAFLD was evaluated after fully adjusting for relevant confounding factors.
- NAFLD was diagnosed with ultrasound in this study. Other methods, such as computed tomography, magnetic resonance imaging, and fibroscan, may provide more precise assessment of NAFLD.
- This was an observational study and the cause–effect relationship is unknown.

INTRODUCTION

Abnormal serum amylase levels generally reflect overall dysfunction of the pancreas or salivary glands. Although the clinical relevance of elevated serum amylase levels has been extensively studied in relation to various conditions, including acute pancreatitis, pancreatic cancer, ectopic amylase-producing tumours, abdominal trauma, and kidney dysfunction [1-5], the clinical relevance of low serum amylase (LSA) has not been examined. LSA is conventionally considered as a crude marker for diffuse pancreas destruction secondary to pancreatic diseases, such as advanced chronic pancreatitis and cystic fibrosis [6,7]. LSA or low pancreatic amylase is also associated with insulin deficiency in patients with type 1 diabetes and in patients with longstanding type 2 diabetes [8-11]. In our recent community-based study, LSA, defined as a serum amylase concentration of < 60 IU/l, was observed in 25% of asymptomatic individuals [12]. LSA is also associated with metabolic syndrome (MetS), a cluster of cardiovascular risk factors, and diabetes [12,13]. However, obesity is thought to be the strongest predictor of LSA in the asymptomatic general population [12].

In the last two decades, there has been a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide, along with an obesity pandemic [14,15]. NAFLD often progresses to a more severe condition, non-alcoholic steatohepatitis (NASH), and increased hepatic fibrosis is a significant histological feature of advanced NASH. NAFLD is considered to be a hepatic manifestation of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MetS and insulin resistance [14-18], which suggests that NAFLD consists of a wide spectrum of cardiometabolic diseases. It is also possible that NAFLD may reflect more pronounced insulin resistance compared with MetS in certain clinical settings, including in individuals without diabetes or obesity [17,19,20]. In this context, we hypothesised that LSA may be associated with NAFLD independently of MetS, type 2 diabetes, and even obesity. The aim of this study was to test this hypothesis and to investigate the clinical relevance of LSA, which is often observed in clinical practice. Therefore, we examined the associations among serum amylase, cardiometabolic risk factors, NAFLD, hepatic fibrosis, MetS, and diabetes in a cross-sectional study of asymptomatic adults.

METHODS

Protocol and subjects

The present report represents a series of observational studies performed in collaboration with Josai University, Sakado, Japan, and Social Insurance Omiya General Hospital that have been conducted to elucidate the relationships between lifestyle-related diseases and cardiometabolic risk factors. We recruited, at random, 2,472 asymptomatic subjects aged 30–79 years who underwent thorough annual medical check-ups, in which the subjects underwent a more extensive array of clinical tests than would be performed in routine check-ups, at the Social Insurance Omiya General Hospital, Saitama, Japan, between April 2009 and March 2010. The protocol

1 was approved by The Ethics Committee of Josai University and the Council of the
2
3
4 Hospital, and informed consent was obtained from all participants.
5
6

7 The exclusion criteria and a flow chart summarizing subject disposition are shown
8
9
10 in *Supplemental Figure 1*. To exclude subjects with latent conditions likely to
11
12 adversely affect the results, we excluded those with C-reactive protein ≥ 10.0 mg/l,
13
14 estimated glomerular filtration rate (eGFR) ≤ 35 ml/min/1.73 m², serum amylase ≤ 30
15
16 IU/l (the lower 5th percentile in an earlier study [12]) or ≥ 200 IU/l based on previous
17
18 reports [21,22], as well as subjects suspected of having cancer. In the current analysis,
19
20 to investigate the potential relationship between serum amylase and cardiometabolic
21
22 features, including NAFLD, we included subjects with a wider range of serum amylase
23
24 levels than the current reference ranges.
25
26
27
28
29
30
31
32

33 Subjects completed a questionnaire recording lifestyle factors, including habitual
34
35 alcohol consumption, which was classified in terms of the frequency (none, occasional,
36
37 and daily) and the amount of ethanol consumed per day (< 20 g, 20–39 g, 40–59 g, or \geq
38
39 60 g). Subjects who habitually consumed ≥ 20 g ethanol per day were excluded from the
40
41 study. Subjects positive for hepatic B virus surface antigen were also excluded. Hepatic
42
43 C virus infection was not measured in this study. We also excluded subjects with other
44
45 active liver diseases not examined, by excluded those with elevated serum liver enzyme
46
47 levels (approximately three times the upper limit of normal): alanine aminotransferase
48
49 (ALT) ≥ 150 IU/ml, aspartate aminotransferase (AST) ≥ 150 IU/ml, or
50
51
52
53
54
55
56
57
58
59
60

1
2 γ -glutamyltransferase (GGT) \geq 150 IU/ml. Consequently, a total of 1,475 individuals
3
4
5 were included in this study.
6
7
8
9

10 **Laboratory measurements**

11
12
13 Laboratory and anthropometric tests, and an abdominal ultrasound were performed in
14
15
16 the early morning after an overnight fast. Serum parameters were measured using an
17
18
19 AutoAnalyzer (Hitachi, Tokyo, Japan). The serum amylase level was measured using an
20
21
22 enzymatic method (L-type Amylase; Wako, Tokyo, Japan) with a detection limit of 1.7
23
24
25 IU/l, and a run-to-run coefficient of variation of $<$ 5.0%.
26
27

28 Abdominal ultrasound for the detection of fatty liver was carried out by **registered**
29
30 **medical sonographers who only work at Social Insurance Omiya General Hospital. The**
31
32 **sonographers were blinded to the subjects' data.** Fatty liver, which was **determined by**
33
34 **comparing liver echogenicity with that of the renal cortex [23],** was defined as NAFLD.
35
36
37 **Additionally,** the severity of NAFLD was graded into three categories: mild NAFLD, a
38
39
40 slight increase in liver echogenicity with normal visualisation of the diaphragm and the
41
42
43 portal veins; moderate NAFLD, a moderate increase in liver echogenicity with slightly
44
45
46 impaired visualisation of the diaphragm and the portal veins; and severe NAFLD, a
47
48
49 substantial increase in liver echogenicity with poor or no visualisation of the diaphragm
50
51
52 and the portal veins [24,25]. **In a previous study, the ultrasonographic steatosis score**
53
54
55 **determined using these grades was highly correlated with the histological grade of**
56
57
58
59
60

1 steatosis ($r = 0.80$, $P < 0.001$), but not with inflammatory activity ($r = 0.10$) or fibrosis
2
3
4 score ($r = 0.19$) [25]. Therefore, the grade of NAFLD in this study probably reflects
5
6
7 overall hepatic fat accumulation, rather than the severity of fibrosis. Since it is possible
8
9
10 that mild NAFLD could include a normal liver, we defined overt NAFLD as moderate
11
12
13 or severe NAFLD. We also examined the findings of gallstones, cholecystectomy, and
14
15
16 splenomegaly, which was defined as a spleen index (calculated as the long dimension \times
17
18
19 short dimension on splenotomogram) ≥ 30 [26,27].
20

21
22 The liver fibrosis scores, the AST/ALT ratio [28] and FIB-4 were calculated in all
23
24 patients, using a previously published formula:

$$25 \text{ FIB-4} = \text{age (years)} \times \text{AST/platelet count (10}^9\text{/l)} \times \text{ALT}^{1/2} \text{ [29]}$$

30
31 The diagnosis of MetS was based on the Adult Treatment Panel-III criteria [30]
32
33 with the following cut-off limits: 1) systolic blood pressure ≥ 130 mmHg or diastolic
34
35 blood pressure ≥ 85 mmHg; 2) triglyceride ≥ 150 mg/dl; 3) high-density
36
37 lipoprotein-cholesterol < 40 mg/dl for men and < 50 mg/dl for women; 4) fasting
38
39 plasma glucose ≥ 100 mg/dl; and 5) waist circumference ≥ 90 cm for men and ≥ 80 cm
40
41 for women. Subjects meeting three or more of these criteria, including treatment for any
42
43 of these disorders, were defined as having MetS. Diabetes was defined as fasting plasma
44
45 glucose ≥ 126 mg/dl or glycosylated haemoglobin (HbA1c) $\geq 6.5\%$ (by the National
46
47 Glycoprotein Standardization Program (NGSP)) according to the American Diabetes
48
49 Association criteria [31], or treatment with oral hypoglycaemic drugs or insulin. HbA1c
50
51
52
53
54
55
56
57
58
59
60

1
2 (Japan Diabetes Society [JDS]) was converted to HbA1c (NGSP) units using the
3
4
5 officially certified formula: $\text{HbA1c (NGSP) (\%)} = 1.02 \times \text{JDS (\%)} + 0.25\%$ [32].
6

7
8 Since serum amylase can be affected by kidney function because of its excretion
9
10 by the kidney [4,5], eGFR was considered as a confounding factor and was calculated
11
12 using the following equation for Japanese subjects [33]: $\text{eGFR (ml/min/1.73 m}^2\text{)} = 194$
13
14 $\times \text{serum Cr}^{-1.094} \times \text{age}^{-0.287}$ (if female) $\times 0.739$. Here, Cr = serum creatinine
15
16
17
18
19 concentration (mg/dl).
20
21
22
23
24

25 **Statistical analysis**

26
27 Data are expressed as the mean \pm standard deviation (SD) or median (interquartile
28
29 range). Subjects were divided into quartiles according to serum amylase levels, where
30
31 Q1 is the highest quartile and Q4 is the lowest quartile. *P*-values for continuous
32
33 variables were determined using analysis of variance (ANOVA) or the Mann-Whitney
34
35 *U* test, and for categorical variables using the χ^2 test. Highly skewed values (ALT, AST,
36
37 GGT, and triglyceride) were log-transformed before analysis. Subjects were also
38
39 stratified into four groups according to the grade of NAFLD (i.e., normal, mild,
40
41 moderate, and severe NAFLD). Multivariate logistic regression models were used to
42
43 examine the associations of quartiles (Q2–4) of serum amylase with any-grade NAFLD
44
45 (NAFLD-AG), and with overt NAFLD relative to Q1, controlling for relevant
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60 confounding factors, including MetS, diabetes, and body mass index (BMI) or waist

1 circumference (WC). To elucidate any association between LSA and NAFLD, we
2
3
4 examined the associations between LSA and NAFLD-AG, and between LSA and overt
5
6
7 NAFLD. This analysis yielded odds ratios (OR) and 95% confidential intervals (95%
8
9
10 CI). Tests for linear trends (P for trend) were calculated by treating the quartiles as a
11
12
13 continuous variable (i.e., 1–4), and the same model analysis was conducted. Statistical
14
15
16 analyses were performed using SPSS software version 18.0 (SPSS-IBM, Chicago, IL,
17
18
19 USA) and Statview version 5.0 (SAS Institute, Cary, NC, USA). Values of $P < 0.05$
20
21
22 were considered to be statistically significant.
23
24
25
26
27

28 RESULTS

29
30 The clinical characteristics of the subjects according to the quartile of serum amylase
31
32 are shown in Table 1. The mean and median values of most clinical parameters,
33
34 including platelet count and eGFR, increased significantly as serum amylase decreased,
35
36
37 although there was a significant trend for subjects with lower amylase levels to be
38
39
40 younger. No significant trend in HbA1c was observed against quartiles of serum
41
42
43 amylase. The prevalence of NAFLD-AG and overt NAFLD increased significantly,
44
45
46 from 22.5% to 42.4% and from 9.2% to 24%, respectively, from the highest (Q1) to the
47
48
49 lowest serum amylase quartile (Q4). There were no significant differences in the
50
51
52 prevalence rates of gallstones, cholecystectomy, or splenomegaly between quartiles,
53
54
55 possibly because of the small numbers of subjects with these features, although the rates
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of cholecystectomy and splenomegaly were higher in Q4 compared with the other quartiles. Log-transformed serum ALT and GGT increased significantly, whereas the AST/ALT ratio and FIB-4 decreased significantly with decreasing serum amylase quartile.

When subjects were stratified according to NAFLD grade, serum amylase decreased significantly with advancing grade of NAFLD (Figure 1). When subjects were further stratified according to sex, there was no significant difference between men and women. However, when the subjects were stratified according to high or low BMI (Figure 2), serum amylase levels were significantly lower in overweight/obese subjects ($\text{BMI} \geq 25.0 \text{ kg/m}^2$, mean \pm SD BMI, $27.3 \pm 2.3 \text{ kg/m}^2$, $n = 1,121$) than in lean subjects ($\text{BMI} < 25.0 \text{ kg/m}^2$, mean \pm SD BMI, $21.6 \pm 2.0 \text{ kg/m}^2$, $n = 354$). Serum amylase levels in lean subjects decreased significantly with advancing grade of NAFLD, whereas those in obese subjects did not. Significant differences between lean and obese subjects were only observed in subjects with a normal liver or mild NAFLD. We did not conduct an analysis by further stratification according to MetS or diabetes because of the small proportion of subjects (both, $< 10\%$).

Multiple logistic regression analysis showed that, compared with the highest quartile of serum amylase ($\geq 90 \text{ IU/l}$, Q1), the lowest quartile ($< 60 \text{ IU/l}$, Q4) was significantly associated with NAFLD-AG even after adjusting for confounders plus MetS or diabetes (Table 2, Models 4 and 5). In these conditions, MetS (OR: 3.66, 95%

1
2 CI: 2.37–5.65) and diabetes (OR: 1.96, 95% CI: 1.25–3.05) were significantly
3
4 associated with Q4 of serum amylase (data not shown). However, these associations
5
6 were markedly attenuated and were no longer statistically significant after adjusting for
7
8 clinical confounders plus BMI or WC (Models 6 and 7), although there was a trend
9
10 towards an association among the quartiles of serum amylase.
11
12
13
14

15
16 When we excluded subjects with mild NAFLD (n = 242) and repeated the
17
18 analysis (Table 3), we detected stronger significant associations between Q4 and overt
19
20 NAFLD. These associations were also moderately attenuated after additional adjustment
21
22 for BMI or WC, but they remained statistically significant (Models 6 and 7). In this
23
24 condition, BMI (OR: 1.65, 95% CI: 1.51–1.80) and WC (OR: 1.21, 95% CI: 1.17–1.25)
25
26 were significantly associated with overt NAFLD (data not shown).
27
28
29
30
31
32
33
34
35

36 DISCUSSION

37
38 For the last few decades, NAFLD has been considered as a manifestation of MetS and
39
40 insulin resistance [14-18]. In this context, the present study showed that LSA was
41
42 significantly associated with NAFLD-AG in asymptomatic adults, independent of MetS,
43
44 diabetes, and sex. Furthermore, LSA may be indicative of overt NAFLD, i.e., moderate
45
46 or severe NAFLD, independent of obesity. These findings are not inconsistent because
47
48 NAFLD may reflect insulin resistance, more so than MetS, in individuals without
49
50 diabetes or obesity [17,19,20].
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This study provided evidence that NAFLD can occur in lean individuals, who accounted for 37.8% (62/104) of subjects with moderate NAFLD and 19.3% (11/57) of subjects with severe NAFLD (Figure 2). This is consistent with the results of multivariate logistic analysis, where there was a significant trend for NAFLD against quartiles of serum amylase, and the significant association between the lowest quartile of serum amylase and NAFLD remained after adjusting for BMI and WC (Tables 2 and 3).

Potential mechanisms of the inverse relationship between serum amylase and NAFLD

We found no significant difference in serum amylase levels between lean and obese subjects with overt NAFLD, suggesting that the effects of obesity on serum amylase are apparent in subjects with a normal liver or with mild NAFLD, but not in subjects with overt NAFLD. Several studies have shown that NAFLD occurs in non-obese people, although the prevalence of NAFLD in non-obese subjects is lower than that in obese subjects [19,20,34]. Therefore, other than obesity, factors not examined in this study might also explain the association between LSA and NAFLD. Insulin resistance and obesity-related hormones, such as leptin, may be potential factors, because insulin resistance and energy imbalance are common pathophysiological findings in obese individuals [17,35]. Indeed, obesity plus insulin resistance is more closely associated

1 with metabolic abnormalities and NAFLD than is obesity without insulin resistance [17].
2
3
4 Hyperinsulinaemia caused by insulin resistance stimulates *de novo* lipogenesis in the
5
6
7 liver through sterol regulatory element binding protein-1c (SREBP-1c) [36],
8
9
10 irrespective of the influx of fatty acid from a meal and lipolysis in adipose tissues.
11
12
13 Additionally, we recently reported a latent association between LSA and insulin
14
15
16 resistance in a small study of asymptomatic middle-aged adults [37], supporting the
17
18
19 hypothesis that LSA may be associated with NAFLD, at least in part through insulin
20
21
22 resistance. However, because insulin resistance, as determined by the homeostasis
23
24
25 model assessment of insulin resistance for example, was not examined in this study,
26
27
28 further large epidemiological studies evaluating insulin resistance are needed to confirm
29
30
31 the current hypothesis.
32

33
34 As another explanation for the inverse relationship between serum amylase and
35
36
37 NAFLD, systemic ectopic fat deposition in organs including the pancreas (i.e., fatty
38
39
40 pancreas) might contribute to the observed associations. This is because intrapancreatic
41
42
43 fat, particularly intralobular pancreatic fat, was reported to be associated with NAFLD
44
45
46 and MetS [38,39]. An animal study showed that obese mice had a heavier pancreas and
47
48
49 more intrapancreatic fat [40]. Therefore, systemic fat deposits in multiple organs may be
50
51
52 a common cause underlying the association between NAFLD and overall pancreatic
53
54
55 dysfunction, which may result in impaired exocrine function, characterised as LSA.

56
57 Gene polymorphisms of patatin-like phospholipase domain containing 3
58
59
60

1 (PNPLA3) may also contribute to the strength of these associations. For example, a
2
3
4 common variant of the PNPLA3 gene (rs738409) was reported to be associated with
5
6
7 increased hepatic fat content (i.e., NAFLD) [41]. In the mouse liver,
8
9
10 adiponutrin/PNPLA3 gene expression is under the direct transcriptional control of
11
12
13 SREBP-1c, in response to insulin [42].
14

15 *Serum amyalse and glucose metabolism*

16
17
18
19 *The prevalence of diabetes increased with decreasing serum amyalse quartile in this*
20
21
22 *study.* However, similar to an earlier study [12], HbA1c was not associated with LSA,
23
24
25 probably because most subjects in the lowest quartile of serum amyalse in this study
26
27
28 had no or only mild insulin resistance or mild hyperinsulinaemia, which is likely
29
30
31 compensated for and results in euglycaemia *or mild hyperglycaemia.* In such conditions,
32
33
34 fasting plasma glucose would increase linearly, as observed in Table 1, in response to
35
36
37 insulin resistance, particularly in the early stage of diabetes [43,44].
38
39
40
41
42
43
44

45 *Serum amyalse and hepatic fibrosis*

46
47
48 To date, some markers have been considered for screening for NAFLD and mild hepatic
49
50
51 fibrosis [45-47]. In this study, while the AST/ALT ratio and Fib-4 decreased
52
53
54 significantly with the decreasing quartile of serum amyalse, the platelet count increased
55
56
57 (Table 1). Consequently, hepatic fibrosis is unlikely to be associated with NAFLD in
58
59
60

1 this study. A plausible explanation is that this study mostly consisted of non-obese
2
3
4 individuals, with a small proportion having MetS and diabetes, resulting in a lower
5
6
7 likelihood of advanced hepatic fibrosis and NASH. In fact, the estimated prevalence of
8
9
10 NASH in this study is quite low when we compare it with the prevalence of NASH in a
11
12
13 nationwide study in Japan. It was reported that approximately 20–25% of patients with
14
15
16 diabetes had NAFLD, a population in which the prevalence of NASH might be 30–40%
17
18
19 [48]. Therefore, the estimated prevalence of NASH might be less than 1% of all of the
20
21
22 subjects in this study. In addition, the fact that more than half of the subjects in this
23
24
25 study had repeatedly undergone detailed medical check-ups may also contribute to the
26
27
28 lower prevalence of NASH, because repeated check-ups may promote consciousness of
29
30
31 healthcare and favourable lifestyles.

32 33 34 35 36 **Limitations**

37
38
39 Several limitations should be mentioned. First, NAFLD was diagnosed by ultrasound
40
41
42 rather than by histological examination, the gold standard technique for the diagnosis of
43
44
45 NAFLD. Thus, NAFLD and the degree of hepatic fibrosis could be inaccurately
46
47
48 evaluated, particularly in the early stages. In earlier studies, ultrasonography had a
49
50
51 sensitivity of 60–94% and a specificity of 66–95% for detecting fatty liver [24,49].
52
53
54 However, its sensitivity is reduced in subjects with a small amount of fat (< 30%), such
55
56
57 as those with mild NAFLD or advanced fibrosis, [14]. To improve the accuracy of
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

detecting and grading of NAFLD, the use of other imaging modalities might be needed, such as magnetic resonance imaging and magnetic resonance spectroscopy, which were reported to provide useful quantitative data in earlier studies [50,51].

Second, hepatitis C virus infection was not measured in this study. However, the prevalence of hepatitis C infection was reported to be 1.5–2.3% in Japan [52]. Low prevalence rates of hepatitis C (< 1.5%) were also recently reported in Asian-Pacific, tropical Latin American, and North American countries [53]. Therefore, hepatitis C infection is unlikely to profoundly modify the association between LSA and NAFLD in this study, although hepatitis C infection can contribute to the development of NAFLD [54]. It is also possible that individuals with primary biliary cirrhosis, autoimmune hepatitis or other forms of liver dysfunction (e.g., haemochromatosis and Wilson disease) were included in the present study, even though we excluded subjects with elevated hepatic enzymes (≥ 150 IU/ml). However, the prevalence of these diseases is quite low in the general population [55-57].

Third, because of the cross-sectional nature of the study, we could not determine the cause–effect relationship between LSA and NAFLD. However, in a previous retrospective study [12], subjects with LSA at baseline were more likely to develop MetS-related metabolic abnormalities 5 years later. Longitudinal prospective studies or clinical intervention trials are needed to elucidate the causality of the associations reported here.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Finally, the clinical relevance of measuring serum amylase remains unclear. The current results suggest that LSA is likely to detect overt NAFLD, but not NASH, which is the most important hepatic disorder. However, from the cardiometabolic perspective, even simple steatosis may be important, particularly in nonobese people, because steatosis may be more strongly associated with insulin resistance than is obesity [17,19,20]. Currently, serum amylase is rarely considered in clinical practice, except in certain situations, such as suspected pancreatitis. Therefore, numerous clinical and animal studies are needed to validate and confirm the clinical relevance of measuring serum amylase before it can be introduced into primary care for the detection of cardiometabolic diseases and NAFLD.

Conclusion

Our results suggest that LSA may be associated with NAFLD, particularly moderate or severe NAFLD, in asymptomatic adults. This association was independent of MetS, diabetes, and obesity. Further studies are needed to confirm the observed associations, and to explore the clinical relevance of LSA.

Acknowledgments None

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interests The authors declare that they have no competing interests.

Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Contributors KN, HM, and MK designed the collaborative project; KN, HO, TM, and HF collected and analysed the data; KN, HO, MS, and YH researched and evaluated the literature; and KN wrote the first draft of the manuscript. All authors reviewed and edited the manuscript, and approved the final version of the manuscript.

Data sharing statement There are no additional data available.

REFERENCES

1. Yegneswaran B, Pitchumoni CS. Yegneswaran B, et al. When should serum amylase and lipase levels be repeated in a patient with acute pancreatitis? *Cleve Clin J Med* 2010;77:230–1.
2. Skrha J, Stěpán J. Clinical significance of amylase isoenzyme determination. *Acta Univ Carol Med Monogr* 1987;120:1–81.
3. Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? *Gastroenterol Clin North Am* 1990;19:793–810.
4. Junge W, Mályusz M, Ehrens HJ. The role of the kidney in the elimination of pancreatic lipase and amylase from blood. *J Clin Chem Clin Biochem* 1985;23:387–92.
5. Collen MJ, Ansher AF, Chapman AB, et al. Serum amylase in patients with renal insufficiency and renal failure. *Am J Gastroenterol* 1990;85:1377–80.
6. Domínguez-Muñoz JE, Pieramico O, Büchler M, et al. Ratios of different serum pancreatic enzymes in the diagnosis and staging of chronic pancreatitis. *Digestion* 1993;54:231–6.
7. Wolf RO, Hubbard VS, Gillard BK, et al. Three methods compared for determination of pancreatic and salivary amylase activity in serum of cystic fibrosis patients. *Clin Chem* 1986;32:296–300.
8. Frier BM, Faber OK, Binder C, et al. The effect of residual insulin secretion on

- 1
2 exocrine pancreatic function in juvenile-onset diabetes mellitus. *Diabetologia*
3
4
5 1978;14:301–4.
6
7
8 9. Dandona P, Freedman DB, Foo Y, et al. Exocrine pancreatic function in diabetes
9
10 mellitus. *J Clin Pathol* 1984;37:302–6
11
12
13 10. Swislocki A, Noth R, Hallstone A, et al. Secretin-stimulated amylase release into
14
15 blood is impaired in type 1 diabetes mellitus. *Horm Metab Res* 2005;37:326–330.
16
17
18 11. Aughsteen AA, Abu-Umair MS, Mahmoud SA. Biochemical analysis of serum
19
20 pancreatic amylase and lipase enzymes in patients with type 1 and type 2 diabetes
21
22 mellitus. *Saudi Med J* 2005;26:73–7.
23
24
25
26
27 12. Nakajima K, Nemoto T, Muneyuki T, et al. Low serum amylase in association with
28
29 metabolic syndrome and diabetes: A community-based study. *Cardiovasc Diabetol*
30
31 2011;10:34.
32
33
34
35
36 13. Lee JG, Park SW, Cho BM, et al. Serum amylase and risk of the metabolic
37
38 syndrome in Korean adults. *Clin Chim Acta* 2011; 412:1848–53
39
40
41
42 14. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of
43
44 an AASLD Single Topic Conference. *Hepatology* 2003;37:1202–19.
45
46
47
48 15. Smith BW, Adams LA. Non-alcoholic fatty liver disease. *Crit Rev Clin Lab Sci*
49
50 2011;48:97–113.
51
52
53
54 16. Stefan N, Häring HU. The metabolically benign and malignant fatty liver. *Diabetes*
55
56 2011;60:2011–7.
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
17. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med* 2008;168:1609–16.
 18. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. *J Clin Endocrinol Metab* 2005; 90:1578–82.
 19. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. *Arch Intern Med* 2004;164:2169–75.
 20. Musso G, Gambino R, Bo S, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. *Diabetes Care* 2008;31:562–8.
 21. Keogh JB, McGeeney KF, Drury MI, et al. Renal clearance of pancreatic and salivary amylase relative to creatinine in patients with chronic renal insufficiency. *Gut* 1978;19:1125–30.
 22. Okura Y, Hayashi K, Shingu T, et al. Diagnostic evaluation of acute pancreatitis in two patients with hypertriglyceridemia. *World J Gastroenterol* 2004;10:3691–5.
 23. Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. *J Ultrasound Med* 2002;21:1023–32.
 24. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. *J Hepatol* 2009;51:433–45.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Shannon A, Alkhoury N, Carter-Kent C, et al. Ultrasonographic quantitative estimation of hepatic steatosis in children With NAFLD. *J Pediatr Gastroenterol Nutr* 2011;53:190–5.
 26. Ishibashi H, Higuchi N, Shimamura R, et al. Sonographic assessment and grading of spleen size. *J Clin Ultrasound* 1991;19:21–5.
 27. Kataoka M, Nakata Y, Maeda T, et al. Ultrasonographic analysis of splenomegaly in patients with sarcoidosis. *Nihon Kyobu Shikkan Gakkai Zasshi* 1990;28:750–5. [In Japanese]
 28. Iacobellis A, Marcellini M, Andriulli A, et al. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. *World J Gastroenterol* 2006;12:7821–5.
 29. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. *Hepatology* 2007;46:32–6.
 30. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735–52.
 31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010;33 Suppl 1:S62–9.
 32. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National

- 1
2 Glycohemoglobin Standardization Program values. *J Diabetes Investig*
3
4
5 2012;3:39–40.
6
7
8 33. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum
9
10 creatinine in Japan. *Am J Kidney Dis* 2009;53:982–92.
11
12
13 34. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country
14
15 has a high prevalence of nonalcoholic fatty liver and significant liver disease.
16
17
18
19
20
21
22
23 35. Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy
24
25 balance. *J Clin Invest* 2011;121:2087–93.
26
27
28 36. Dentin R, Pégrier JP, Benhamed F, et al. Hepatic glucokinase is required for the
29
30 synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene
31
32 expression. *J Biol Chem* 2004;279:20314–26.
33
34
35
36 37. Muneyuki T, Nakajima K, Aoki A, et al. Latent associations of low serum amylase
37
38 with decreased plasma insulin levels and insulin resistance in asymptomatic
39
40 middle-aged adults. *Cardiovasc Diabetol* 2012;11:80.
41
42
43
44
45 38. van Geenen EJ, Smits MM, Schreuder TC, et al. Nonalcoholic fatty liver disease is
46
47 related to nonalcoholic fatty pancreas disease. *Pancreas* 2010;39:1185–90.
48
49
50
51 39. Sepe PS, Ohri A, Sanaka S, et al. A prospective evaluation of fatty pancreas by
52
53 using EUS. *Gastrointest Endosc* 2011;73:987–93.
54
55
56
57 40. Mathur A, Marine M, Lu D, et al. Nonalcoholic fatty pancreas disease. *HPB*
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- (Oxford) 2007;9:312–8.
41. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of
patatin-like phospholipase domain containing 3 gene (PNPLA3) on the
susceptibility and histological severity of nonalcoholic fatty liver disease.
Hepatology 2011;53:1883–94.
42. Dubuquoy C, Robichon C, Lasnier F, et al. Distinct regulation of
adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and
SREBP1c in mouse and human hepatocytes. *J Hepatol* 2011;55:145–53.
43. Reaven G. Wanted!: a standardized measurement of plasma insulin concentration.
Arterioscler Thromb Vasc Biol 2011;31:954–55.
44. Robins SJ, Lyass A, Zachariah JP, et al. Insulin resistance and the relationship of a
dyslipidemia to coronary heart disease: the Framingham Heart Study. *Arterioscler
Thromb Vasc Biol* 2011;31:1208–14.
45. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase
in chronic hepatitis. Relationship to cirrhosis. *Gastroenterology* 1988;95:734–9.
46. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive
system that identifies liver fibrosis in patients with NAFLD. *Hepatology*
2007;45:846–54.
47. McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring
systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty

- 1
2 liver disease. *Gut* 2010;59:1265–9.
3
4
5 48. Okanoue T, Umemura A, Yasui K, et al. Nonalcoholic fatty liver disease and
6
7 nonalcoholic steatohepatitis in Japan. *J Gastroenterol Hepatol* 2011;26 Suppl
8
9 1:153–62.
10
11
12
13 49. Joseph AE, Saverymuttu SH, al-Sam S, et al. Comparison of liver histology with
14
15 ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol*
16
17 1991;43:26–31.
18
19
20
21
22 50. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and
23
24 quantification of liver steatosis by ultrasound, computed tomography and magnetic
25
26 resonance. *J Hepatol* 2009;51:433–45.
27
28
29
30
31 51. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver
32
33 disease and advanced fibrosis in Hong Kong Chinese: a population study using
34
35 proton-magnetic resonance spectroscopy and transient elastography. *Gut*
36
37 2012;61:409–15.
38
39
40
41
42 52. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus
43
44 infection. *Lancet Infect Dis* 2005;5:558–67.
45
46
47
48 53. Hanafiah KM, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C
49
50 virus infection: New estimates of age-specific antibody to hepatitis C virus
51
52 seroprevalence. *Hepatology* 2012 Nov 21.
53
54
55
56
57 54. Pattullo V, Douglas MW, George J. Organelle dysfunction in hepatitis C
58
59
60

1 virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?
2
3

4 *Expert Rev Gastroenterol Hepatol* 2011;5:265–77.
5
6

7 55. Kumagi T, Heathcote EJ. Primary biliary cirrhosis. *Orphanet J Rare Dis* 2008;3:1.
8
9

10 56. Strassburg CP. Autoimmune hepatitis. *Best Pract Res Clin Gastroenterol*
11
12

13 2010;24:667–82.
14
15

16 57. Oh RC, Husted TR. Causes and evaluation of mildly elevated liver transaminase
17
18

19 levels. *Am Fam Physician* 2011;84:1003–8.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1 Serum amylase levels according to the grade of NAFLD and sex. Serum amylase levels decreased significantly with advancing grade of NAFLD in both sexes (ANOVA, both $P = 0.0001$). There was no significant difference between men and women (two-way ANOVA, $P = 0.45$). *Number of subjects in each group. Bars represent standard errors.

Figure 2 Serum amylase levels according to the grade of NAFLD and obesity. Obesity was defined as $BMI \geq 25.0 \text{ kg/m}^2$. Serum amylase levels decreased significantly with advancing grade of NAFLD in lean subjects (ANOVA, $P = 0.01$), but not in obese subjects ($P = 0.33$). An overall significant difference was observed between lean and obese subjects (two-way ANOVA, $P = 0.03$). *Number of subjects in each group; † $P = 0.0001$ and ‡ $P = 0.02$ for lean versus obese subjects (Mann–Whitney U test). Bars represent standard errors.

Supplement Figure 1

Exclusion criteria of subjects and flow chart

Table 1. Characteristics of subjects stratified according to quartiles of serum amylase

	Total	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> value
n	1,475	369	371	381	354	
Age, y	55.1 ± 12.2	58.4 ± 11.8	56.4 ± 12.2	52.9 ± 11.7	52.7 ± 12.0	< 0.0001
Men, n (%)	747 (50.6)	178 (48.2)	176 (47.4)	205 (53.8)	188 (53.1)	0.19
BMI, kg/m ²	23.0 ± 3.2	21.9 ± 2.7	22.6 ± 3.2	23.3 ± 3.1	24.1 ± 3.4	< 0.0001
WC, cm	80.8 ± 8.9	78.2 ± 8.3	79.9 ± 8.8	81.8 ± 8.8	83.2 ± 9.1	< 0.0001
Systolic blood pressure, mmHg	120 ± 18.9	119 ± 18.5	119 ± 18.7	120 ± 18.9	123 ± 19.1	0.007
Diastolic blood pressure, mmHg	74.1 ± 12.6	72.6 ± 12.2	73.1 ± 11.9	74.5 ± 13.4	76.1 ± 12.4	0.0009
Platelet count, 10 ⁹ /L	235 ± 53.4	228 ± 53.8	235 ± 53.1	237 ± 51.1	241 ± 55.2	0.01
ALT, IU/l	18 (14–25)	18 (14–23)	17 (14–23)	18 (14–25)	19 (14–29)	< 0.0001
AST, IU/l	20 (17–24)	21 (19–25)	20 (17–24)	19 (17–23)	20 (17–24)	0.04
AST/ALT	1.15 ± 0.36	1.24 ± 0.35	1.20 ± 0.37	1.12 ± 0.33	1.04 ± 0.35	< 0.0001

FIB-4	1.13 (0.82–1.52)	1.33 (0.98–1.76)	1.20 (0.89–1.59)	1.05 (0.76–1.38)	0.98 (0.70–1.36)	< 0.0001
GGT, IU/l	22 (16–33)	20 (15–31)	20 (16–30)	23 (16–34)	24 (17–38)	0.0009
C-reactive protein	0.4 (0.3–0.8)	0.3 (0.3–0.63)	0.4 (0.3–0.8)	0.4 (0.3–0.8)	0.5 (0.3–1.1)	< 0.0001
Amylase, IU/l	77.3 ± 24.9	110 ± 22.0	81.3 ± 4.7	66.6 ± 4.1	50.3 ± 7.0	—
(range)	(30–200)	(90–200)	(74–89)	(60–73)	(30–59)	
Triglyceride, mg/dl	88 (64–128)	83 (63–121)	84 (62–123)	88 (65–128)	100 (65–143)	0.001
HDL-cholesterol, mg/dl	61.2 ± 15.0	64.2 ± 15.4	62.6 ± 14.8	59.8 ± 14.6	58.3 ± 14.5	< 0.0001
Fasting plasma glucose, mg/dl	99.6 ± 16.7	97.5 ± 13.4	97.4 ± 11.4	101 ± 19.4	103 ± 20.4	< 0.0001
HbA1c (NGSP), %	5.7 ± 0.6	5.7 ± 0.5	5.7 ± 0.4	5.7 ± 0.6	5.8 ± 0.7	0.14
eGFR, ml/min/1.73m ²	75.0 ± 13.9	71.0 ± 14.3	74.3 ± 12.9	76.0 ± 14.2	78.7 ± 13.1	< 0.0001
ATP-III-Metabolic syndrome, n (%)	139 (9.4)	16 (4.3)	23 (6.2)	47 (12.3)	53 (15.0)	< 0.0001
Diabetes, n (%)	114 (7.7)	19 (5.1)	17 (4.6)	34 (8.9)	44 (12.4)	0.0002
NAFLD of all grades, n (%)	463 (31.4)	83 (22.5)	97 (26.1)	133 (34.9)	150 (42.4)	< 0.0001

Moderate to severe NAFLD, n (%)	221 (15.0)	34 (9.2)	42 (11.3)	60 (15.7)	85 (24.0)	< 0.0001
Gallstones, n (%)	81 (5.5)	21 (5.7)	20 (5.4)	24 (6.3)	16 (5.2)	0.76
Cholecystectomy, n (%)	23 (1.6)	5 (1.4)	3 (0.8)	5 (1.3)	10 (2.8)	0.15
Splenomegaly, n (%)	9 (0.6)	1 (0.3)	1 (0.3)	0	7 (2.0)	—*
Medical history of						
Cardiovascular diseases, n (%)	55 (3.7)	11 (3.0)	20 (5.4)	11 (2.9)	13 (3.7)	0.24
Stroke, n (%)	26 (1.8)	12 (3.3)	6 (1.6)	4 (1.1)	4 (1.1)	0.08
Medications for						
Hypertension, n (%)	237 (16.1)	64 (17.3)	47 (12.7)	67 (17.6)	59 (16.7)	0.22
Hypercholesterolemia, n (%)	177 (12.0)	56 (15.2)	43 (11.6)	34 (8.9)	44 (12.4)	0.07
Diabetes, n (%)	56 (3.8)	12 (3.3)	12 (3.2)	15 (3.9)	17 (4.8)	0.65
Current smoker, n (%)	273 (18.5)	40 (10.8)	50 (13.5)	86 (22.6)	97 (27.4)	< 0.0001
Everyday alcohol consumers, n (%)	229 (15.5)	51 (13.8)	59 (15.9)	66 (17.3)	53 (15.0)	0.61

Regular exercise, n (%)	507 (34.4)	144 (39.0)	135 (36.4)	125 (32.9)	103 (29.1)	0.03
-------------------------	------------	------------	------------	------------	------------	------

Data are means ±SD and medians (interquartile range). *P*-values for continuous variables and categorical variables were determined by analysis of variance and the χ^2

test, respectively. Regular exercise: ≥ 30 min exercise per session at least twice a week.

*Statistical analysis was not performed because of the small number of subjects with splenomegaly.

For peer review only

Table 2. Odds ratios for NAFLD-AG according to serum amylase quartiles

Serum amylase quartiles	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> for trend
n	369	371	381	354	
Model 1	1	1.22 (0.87–1.71)	1.85 (1.34–2.55)	2.53 (1.84–3.50)	< 0.0001
Model 2	1	1.28 (0.91–1.81)	1.96 (1.39–2.74)	2.74 (1.95–3.85)	< 0.0001
Model 3	1	1.35 (0.93–1.97)	2.03 (1.41–2.94)	2.41 (1.66–3.51)	< 0.0001
Model 4	1	1.25 (0.86–1.82)	1.83 (1.26–2.65)	2.18 (1.49–3.18)	< 0.0001
Model 5	1	1.31 (0.90–1.90)	2.00 (1.39–2.89)	2.36 (1.62–3.44)	< 0.0001
Model 6	1	0.99 (0.66–1.49)	1.34 (0.89–2.01)	1.42 (0.94–2.15)	0.04
Model 7	1	1.02 (0.68–1.53)	1.30 (0.87–1.94)	1.49 (0.99–2.24)	0.03

Model 1: unadjusted.

Model 2: adjusted for age, sex, and current smoking (*versus* non-smokers).

Model 3: Model 2 plus adjustment for log-transformed ALT, regular exercise (*versus* infrequent exercise), daily alcohol consumption (*versus* infrequent/no alcohol)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

consumption), eGFR, past history of heart diseases and stroke, and medications for hypertension, diabetes, and dyslipidemia.

Model 4: Model 3 plus adjustment for diabetes, but excluding medications for hypertension, diabetes, and dyslipidemia.

Model 5: Model 3 plus adjustment for metabolic syndrome, but excluding medications for hypertension, diabetes, and dyslipidemia.

Model 6: Model 3 plus adjustment for BMI.

Model 7: Model 3 plus adjustment for WC.


For peer review only

Table 3. Odds ratios of each serum amylase for NAFLD of moderate or severe grade


Serum amylase quartiles	Q1 (Highest)	Q2	Q3	Q4 (Lowest)	<i>P</i> for trend
N*	320	316	308	289	
Model 1	1	1.29 (0.80–2.09)	2.04 (1.29–3.20)	3.51 (2.27–5.42)	< 0.0001
Model 2	1	1.36 (0.83–2.22)	2.14 (1.33–3.44)	3.81 (2.40–6.05)	< 0.0001
Model 3	1	1.61 (0.91–2.86)	2.32 (1.32–4.07)	3.45 (1.99–6.00)	< 0.0001
Model 4	1	1.48 (0.84–2.64)	2.11 (1.19–3.73)	2.97 (1.70–5.20)	< 0.0001
Model 5	1	1.56 (0.89–2.75)	2.32 (1.33–4.04)	3.26 (1.88–5.66)	< 0.0001
Model 6	1	1.05 (0.54–2.03)	1.44 (0.76–2.72)	2.01 (1.07–3.78)	0.01
Model 7	1	1.06 (0.55–2.05)	1.37 (0.73–2.59)	2.06 (1.09–3.87)	0.01

*Subjects with mild NAFLD (n = 242) were excluded from this analysis. Models 1–7 are the same as those in **Table 2**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



117x90mm (300 x 300 DPI)



129x90mm (300 x 300 DPI)

view only

Exclusion criteria of subjects and flow chart

